<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">TAU</journal-id>
<journal-id journal-id-type="hwp">sptau</journal-id>
<journal-title>Therapeutic Advances in Urology</journal-title>
<issn pub-type="ppub">1756-2872</issn>
<issn pub-type="epub">1756-2880</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1756287212453079</article-id>
<article-id pub-id-type="publisher-id">10.1177_1756287212453079</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Current approaches to bone-targeted therapy in genitourinary malignancies</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Mulders</surname><given-names>Peter F.</given-names></name>
</contrib>
<aff id="aff1-1756287212453079">Department of Urology, Radboud University Medical Centre, PO Box 9101, HB 6500, Nijmegen, The Netherlands</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-1756287212453079"><email>p.mulders@uro.umcn.nl</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>10</month>
<year>2012</year>
</pub-date>
<volume>4</volume>
<issue>5</issue>
<fpage>219</fpage>
<lpage>232</lpage>
<permissions>
<copyright-statement>© The Author(s), 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Bone metastases in patients with genitourinary cancers are associated with increased risk for skeletal-related events including pathologic fractures, spinal cord compression, and the requirement for surgery or palliative radiotherapy to bone. The nitrogen-containing bisphosphonate zoledronic acid and the monoclonal antibody against RANK, denosumab, are approved for the prevention of skeletal-related events in genitourinary cancers. These agents have different mechanisms of action and pharmacokinetic profiles, and while both are effective in reducing the risk of skeletal-related events, other clinical effects differ. There is evidence for direct and indirect anticancer activity with zoledronic acid from preclinical studies and emerging data from clinical studies suggesting an effect on patient survival. Potential anticancer mechanisms include inhibition of angiogenesis, enhanced immune surveillance via stimulation of γδ T cells, and reduction of circulating tumor cells. A synergistic effect of chemotherapy plus zoledronic acid has also been suggested. Further research is ongoing regarding the roles of these antiresorptive therapies in patients with bone metastases or at high risk for malignant spread to skeletal sites.</p>
</abstract>
<kwd-group>
<kwd>anticancer</kwd>
<kwd>antiresorptive therapy</kwd>
<kwd>bisphosphonate</kwd>
<kwd>bone metastases</kwd>
<kwd>denosumab</kwd>
<kwd>genitourinary cancer</kwd>
<kwd>skeletal-related events</kwd>
<kwd>zoledronic acid</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1756287212453079" sec-type="intro">
<title>Introduction</title>
<p>Patients with genitourinary (GU) malignancies are at risk for deterioration of bone throughout the disease continuum as a result of treatment, underlying disease, or both [<xref ref-type="bibr" rid="bibr13-1756287212453079">Coleman, 2001</xref>; <xref ref-type="bibr" rid="bibr64-1756287212453079">Saad <italic>et al</italic>. 2006</xref>]. Androgen-deprivation therapy for prostate cancer is associated with decreased bone mineral density, increased risk for osteoporosis, and in one large meta-analysis, a 1.17-fold relative increase in the risk of skeletal fractures [<xref ref-type="bibr" rid="bibr53-1756287212453079">Mittan <italic>et al</italic>. 2002</xref>; <xref ref-type="bibr" rid="bibr72-1756287212453079">Serpa Neto <italic>et al</italic>. 2010</xref>]. Moreover, a significant proportion of patients with GU malignancies may develop metastatic skeletal involvement, further exacerbating loss of structural bone integrity [<xref ref-type="bibr" rid="bibr13-1756287212453079">Coleman, 2001</xref>; <xref ref-type="bibr" rid="bibr85-1756287212453079">Zekri <italic>et al</italic>. 2001</xref>; <xref ref-type="bibr" rid="bibr81-1756287212453079">Woodward <italic>et al</italic>. 2011</xref>]. Bone metastases are associated with a vicious cycle of bone destruction and tumor growth. As a result, patients with bone metastases typically experience severe bone pain and are at high risk of developing potentially debilitating skeletal-related events (SREs) including pathological fractures or spinal cord compression that may require surgical or radiotherapy intervention [<xref ref-type="bibr" rid="bibr12-1756287212453079">Coleman, 1997</xref>; <xref ref-type="bibr" rid="bibr68-1756287212453079">Saad and Lipton, 2005</xref>]. Inevitably, SREs reduce a patient’s quality of life and functional independence, which are of particular relevance in patients who have a long life expectancy [<xref ref-type="bibr" rid="bibr63-1756287212453079">Saad, 2008</xref>].</p>
<p>Antiresorptive therapies have demonstrated favorable efficacy in reducing bone pain and delaying the onset and reducing the risk of SREs [<xref ref-type="bibr" rid="bibr66-1756287212453079">Saad <italic>et al</italic>. 2002</xref>, <xref ref-type="bibr" rid="bibr67-1756287212453079">2004</xref>; <xref ref-type="bibr" rid="bibr46-1756287212453079">Lipton <italic>et al</italic>. 2003</xref>; <xref ref-type="bibr" rid="bibr62-1756287212453079">Rosen <italic>et al</italic>. 2004</xref>; <xref ref-type="bibr" rid="bibr6-1756287212453079">Bouganim <italic>et al</italic>. 2011</xref>; <xref ref-type="bibr" rid="bibr26-1756287212453079">Fizazi <italic>et al</italic>. 2011</xref>; <xref ref-type="bibr" rid="bibr33-1756287212453079">Henry <italic>et al</italic>. 2011</xref>]. There are two main classes of antiresorptive compounds currently approved for prevention of SREs in patients with GU malignancies: bisphosphonates (BPs) and the more recently developed monoclonal antibody against the receptor activator of nuclear factor κB ligand (RANKL), denosumab (Dmab). There are important differences in the antiresorptive mechanisms of action and pharmacokinetics of BPs and Dmab that may result in differences in efficacy and safety, particularly in oncology settings. This review focuses on fundamental differences between the two antiresorptive therapies and the potential implications for use of these agents in the context of GU malignancies.</p>
</sec>
<sec id="section2-1756287212453079">
<title>Mechanism of action of antiresorptive therapies in bone</title>
<p>Bisphosphonates are synthetic analogues of pyrophosphate that are resistant to enzymatic degradation through the substitution of the central oxygen atom by a carbon atom [<xref ref-type="bibr" rid="bibr83-1756287212453079">Yuasa <italic>et al</italic>. 2007</xref>; <xref ref-type="bibr" rid="bibr31-1756287212453079">Green and Clezardin, 2010</xref>]. Variation in the substituent groups bound to the central carbon account for differences in therapeutic activities of the BPs. There are two broad classifications of BPs: non-nitrogen-containing BPs and the most recent generation, nitrogen-containing BPs (NBPs), which have greater antiresorptive activity. Non–nitrogen-containing BPs are internalized and metabolized by osteoclasts to nonhydrolyzable adenosine triphosphate (ATP) analogues that inhibit osteoclast activity and lead to apoptosis [<xref ref-type="bibr" rid="bibr83-1756287212453079">Yuasa <italic>et al</italic>. 2007</xref>]. In contrast, the NBPs inhibit farnesyl pyrophosphate synthase in the mevalonate pathway, thereby inhibiting the post-translational prenylation and function of small guanosine 5′-triphosphatase (GTPase) proteins. Small GTPase proteins modulate signaling pathways that are essential for osteoclast function and survival [<xref ref-type="bibr" rid="bibr31-1756287212453079">Green and Clezardin, 2010</xref>].</p>
<p>Denosumab inhibits osteoclast-mediated bone destruction by binding and neutralizing RANKL [<xref ref-type="bibr" rid="bibr9-1756287212453079">Castellano <italic>et al</italic>. 2011</xref>]. Soluble and membrane-bound RANKL, synthesized by various cell types including osteoblasts and activated T cells, plays a key role in normal bone remodeling by binding and activating the receptor activator of nuclear factor κB (RANK) receptor on the surface of osteoclasts. Activation of RANK modulates several signal transduction pathways, including protein kinase pathways and activation of the transcription factor nuclear factor κB that leads to stimulation of osteoclast formation, function, and survival and, as a result, increased bone resorption. Inhibition of RANKL by high-affinity binding to Dmab prevents activation of RANK, thereby reducing bone resorption and increasing bone volume, density, and strength [<xref ref-type="bibr" rid="bibr9-1756287212453079">Castellano <italic>et al</italic>. 2011</xref>].</p>
</sec>
<sec id="section3-1756287212453079">
<title>Pharmacokinetics of antiresorptive therapies</title>
<p>Following intravenous administration, BPs are rapidly cleared from the systemic circulation by deposition in bone and renal excretion of unmetabolized drug within a few hours [<xref ref-type="bibr" rid="bibr10-1756287212453079">Chen <italic>et al</italic>. 2002</xref>; <xref ref-type="bibr" rid="bibr42-1756287212453079">Kimmel, 2007</xref>]. Bisphosphonates are retained in the bone via binding to areas of exposed hydroxyapatite crystals where they act to reduce bone resorption by osteoclasts. During bone remodeling, low levels of BP are released from bone, accounting for the longer terminal phase of elimination. Pharmacokinetics of the NBP zoledronic acid (ZOL) measured in patients with bone metastases demonstrate multiphasic plasma disposition with plasma half lives of 0.2 and 1.4 h initially, followed by longer half lives of 39 and 4526 h for subsequent elimination phases of very low concentrations between day 2 and day 28 post dose [<xref ref-type="bibr" rid="bibr10-1756287212453079">Chen <italic>et al</italic>. 2002</xref>]. This study confirmed that the antiresorptive effects of ZOL persisted over 28 days, thus supporting monthly infusions of ZOL. Furthermore, a study evaluating adjuvant endocrine therapy in combination with ZOL in women with early-stage breast cancer demonstrated that ZOL improved bone mineral density (BMD) for 2 years after discontinuation of ZOL therapy, suggesting a prolonged duration of effect [<xref ref-type="bibr" rid="bibr29-1756287212453079">Gnant <italic>et al</italic>. 2008</xref>].</p>
<p>Denosumab is administered subcutaneously every 4 weeks in patients with bone metastases; however, unlike BPs, Dmab is distributed systemically and follows nonlinear, dose-dependent pharmacokinetics with detectable serum levels as early as 1 h post dose and maximum serum concentrations within 1–3 weeks. Following a single 3 mg/kg injection, the elimination half life for Dmab ranged from 33.3 to 46.3 days in patients with multiple myeloma and breast cancer, respectively [<xref ref-type="bibr" rid="bibr5-1756287212453079">Body <italic>et al</italic>. 2006</xref>]. These properties have clinical implications for specificity of action and duration of benefit. Because Dmab is not retained at its site of action in the bone, the antiresorptive effect of this agent is quickly reversed after the drug is cleared [<xref ref-type="bibr" rid="bibr52-1756287212453079">Miller <italic>et al</italic>. 2008</xref>].</p>
</sec>
<sec id="section4-1756287212453079">
<title>Incidence of skeletal-related events and clinical efficacy of antiresorptive agents</title>
<p>The clinical efficacy of antiresorptive agents is based on their ability to inhibit osteoclast-mediated bone degradation and thus prevent or delay development of SREs (<xref ref-type="table" rid="table1-1756287212453079">Table 1</xref>) [<xref ref-type="bibr" rid="bibr66-1756287212453079">Saad <italic>et al</italic>. 2002</xref>, <xref ref-type="bibr" rid="bibr67-1756287212453079">2004</xref>; <xref ref-type="bibr" rid="bibr21-1756287212453079">Dearnaley <italic>et al</italic>. 2003</xref>, <xref ref-type="bibr" rid="bibr20-1756287212453079">2009</xref>; <xref ref-type="bibr" rid="bibr24-1756287212453079">Ernst <italic>et al</italic>. 2003</xref>; <xref ref-type="bibr" rid="bibr46-1756287212453079">Lipton <italic>et al</italic>. 2003</xref>; <xref ref-type="bibr" rid="bibr73-1756287212453079">Small <italic>et al</italic>. 2003</xref>; <xref ref-type="bibr" rid="bibr68-1756287212453079">Saad and Lipton, 2005</xref>; <xref ref-type="bibr" rid="bibr48-1756287212453079">Mason <italic>et al</italic>. 2007</xref>; <xref ref-type="bibr" rid="bibr25-1756287212453079">Fizazi <italic>et al</italic>. 2009</xref>, <xref ref-type="bibr" rid="bibr26-1756287212453079">2011</xref>; <xref ref-type="bibr" rid="bibr84-1756287212453079">Zaghloul <italic>et al</italic>. 2010</xref>; <xref ref-type="bibr" rid="bibr33-1756287212453079">Henry <italic>et al</italic>. 2011</xref>]. Placebo-controlled trials of antiresorptive therapy in patients with GU malignancies and bone metastases show that without treatment, 44–90% of patients will experience at least 1 SRE [<xref ref-type="bibr" rid="bibr66-1756287212453079">Saad <italic>et al</italic>. 2002</xref>, <xref ref-type="bibr" rid="bibr67-1756287212453079">2004</xref>; <xref ref-type="bibr" rid="bibr46-1756287212453079">Lipton <italic>et al</italic>. 2003</xref>; <xref ref-type="bibr" rid="bibr68-1756287212453079">Saad and Lipton, 2005</xref>; <xref ref-type="bibr" rid="bibr84-1756287212453079">Zaghloul <italic>et al</italic>. 2010</xref>; <xref ref-type="bibr" rid="bibr81-1756287212453079">Woodward <italic>et al</italic>. 2011</xref>]. In the absence of bone-targeted therapy, approximately half of patients with bone metastases from castration-resistant prostate cancer (CRPC) experienced an SRE [<xref ref-type="bibr" rid="bibr67-1756287212453079">Saad <italic>et al</italic>. 2004</xref>] and 79% of patients with bone metastases from renal cell carcinoma (RCC) experienced an SRE [<xref ref-type="bibr" rid="bibr68-1756287212453079">Saad and Lipton,. 2005</xref>]. A small, prospective, placebo-controlled trial in patients with bone metastases from bladder cancer reported that 90% of patients in the placebo group developed an SRE [<xref ref-type="bibr" rid="bibr84-1756287212453079">Zaghloul <italic>et al</italic>. 2010</xref>]. The skeletal morbidity rate (mean SREs per patient years) for patients with advanced prostate cancer with a history of bone metastases was 1.49 SREs per patient year in 15 months in one study [<xref ref-type="bibr" rid="bibr66-1756287212453079">Saad <italic>et al</italic>. 2002</xref>], and in patients with RCC and at least one site of bone metastases, the mean skeletal morbidity rate was 3.38 [<xref ref-type="bibr" rid="bibr46-1756287212453079">Lipton <italic>et al</italic>. 2003</xref>].</p>
<table-wrap id="table1-1756287212453079" position="float">
<label>Table 1.</label>
<caption>
<p>Efficacy of antiresorptive therapy for skeletal-related event prevention in patients with genitourinary cancers.</p>
</caption>
<graphic alternate-form-of="table1-1756287212453079" xlink:href="10.1177_1756287212453079-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Study</th>
<th align="left"><italic>N</italic></th>
<th align="left">Study population</th>
<th align="left">Arms</th>
<th align="left">Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="3"><xref ref-type="bibr" rid="bibr66-1756287212453079">Saad <italic>et al</italic>. [2002]</xref></td>
<td rowspan="3">643</td>
<td rowspan="3">CRPC (asymptomatic or minimally symptomatic)</td>
<td rowspan="3">ZOL 4 mg every 3 weeks <italic>versus</italic> PBO</td>
<td>At 15-month follow up (<italic>N</italic> = 643):</td>
</tr>
<tr>
<td>ZOL ⬇SREs (33.2% <italic>versus</italic> 44.2%, <italic>p</italic> = 0.021)</td>
</tr>
<tr>
<td>No difference in time to disease progression Trend toward ⬆OS with ZOL At 24-month follow up (<italic>n</italic> = 122):</td>
</tr>
<tr>
<td rowspan="2"><xref ref-type="bibr" rid="bibr67-1756287212453079">Saad <italic>et al</italic>. [2004]</xref></td>
<td rowspan="2"/>
<td rowspan="2"/>
<td rowspan="2">for up to 24 months</td>
<td>ZOL ⬇SREs (38% <italic>versus</italic> 49%, <italic>p</italic> = 0.028)</td>
</tr>
<tr>
<td>ZOL ⬆time to first SRE (488 <italic>versus</italic> 321 days, <italic>p</italic> = 0.009)</td>
</tr>
<tr>
<td rowspan="3"><xref ref-type="bibr" rid="bibr46-1756287212453079">Lipton <italic>et al</italic>. [2003]</xref></td>
<td rowspan="3">74</td>
<td rowspan="3">RCC with bone metastases</td>
<td rowspan="3">ZOL 4 mg <italic>versus</italic> PBO every 3 weeks for 9 months</td>
<td>ZOL ⬇SREs 50% (37% <italic>versus</italic> 74%, <italic>p</italic> = 0.015)</td>
</tr>
<tr>
<td>ZOL ⬇SMR (2.68 <italic>versus</italic> 3.38, <italic>p</italic> = 0.014)</td>
</tr>
<tr>
<td>ZOL ⬇SRE risk by 61% (HR = 0.394, <italic>p</italic> = 0.008)</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr68-1756287212453079">Saad and Lipton [2005]</xref></td>
<td>46</td>
<td/>
<td>21 months</td>
<td>ZOL ⬇SREs (41% <italic>versus</italic> 79%, <italic>p</italic> = 0.011)</td>
</tr>
<tr>
<td rowspan="3"><xref ref-type="bibr" rid="bibr84-1756287212453079">Zaghloul <italic>et al</italic>. [2010]</xref></td>
<td rowspan="3">40</td>
<td rowspan="3">Bladder cancer with bone metastases</td>
<td rowspan="3">Palliative radiation to affect bone followed by ZOL 4 mg or PBO monthly for 6 months</td>
<td>ZOL ⬇SREs (60% <italic>versus</italic> 90%; <italic>p</italic> = 0.010)</td>
</tr>
<tr>
<td>ZOL ⬇SMR (0.95 <italic>versus</italic> 2.05, <italic>p</italic> = 0.001)</td>
</tr>
<tr>
<td>ZOL ⬆1-year survival (36.3% <italic>versus</italic> 0%, <italic>p</italic> = 0.004)</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr73-1756287212453079">Small <italic>et al</italic>. [2003]</xref></td>
<td>350</td>
<td>CRPC with symptomatic bone metastases</td>
<td>PAM 90 mg <italic>versus</italic> PBO every 3 weeks for 27 weeks</td>
<td>No significant difference in SREs or palliation of bone pain</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr24-1756287212453079">Ernst <italic>et al</italic>. [2003]</xref></td>
<td>209</td>
<td>CRPC with symptomatic bone metastases</td>
<td>Mitoxantrone and prednisone ± CLO 1500 mg every 3 weeks until progression</td>
<td>No significant difference in palliative response (pain intensity and analgesic use), PFS, or OS</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr48-1756287212453079">Mason <italic>et al</italic>. [2007]</xref></td>
<td>508</td>
<td>PC with no evidence of bone metastases (T2–T4)</td>
<td>Oral CLO 2080 mg/day <italic>versus</italic> PBO for up to 5 years</td>
<td>No difference in symptomatic bone metastases or death from PC</td>
</tr>
<tr>
<td rowspan="2"><xref ref-type="bibr" rid="bibr21-1756287212453079">Dearnaley <italic>et al</italic>. [2003</xref>, <xref ref-type="bibr" rid="bibr20-1756287212453079">2009</xref>]</td>
<td rowspan="2">311</td>
<td rowspan="2">Hormone-sensitive PC with bone metastases</td>
<td rowspan="2">Oral CLO 2080 mg/day or PBO for up to 3 yr</td>
<td>Trend toward ⬆OS with CLO (HR = 0.80, <italic>P</italic> = .082) at 5 yr</td>
</tr>
<tr>
<td>CLO ⬆OS (HR = 0.77; <italic>P</italic> = .032) with median follow-up of 11.5 yr</td>
</tr>
<tr>
<td rowspan="2"><xref ref-type="bibr" rid="bibr25-1756287212453079">Fizazi <italic>et al</italic>. [2009]</xref></td>
<td rowspan="2">111 (Dmab <italic>n</italic> = 74; BP <italic>n</italic> = 37)</td>
<td rowspan="2">Solid tumors including PC with bone metastases and elevated NTX despite BP treatment for ≥ 8 weeks</td>
<td rowspan="2">Dmab 180 mg subcutaneously every 4 weeks or every 12 weeks; ZOL or PAM every 4 weeks</td>
<td>Dmab ⬇NTX (71% <italic>versus</italic> 29%; <italic>p</italic> &lt; 0.001)</td>
</tr>
<tr>
<td>First on-study SREs were lower with Dmab but not significantly different</td>
</tr>
<tr>
<td rowspan="2"><xref ref-type="bibr" rid="bibr33-1756287212453079">Henry <italic>et al</italic>. [2011]</xref></td>
<td rowspan="2">1776</td>
<td rowspan="2">Solid tumors or MM (excluding BC and PC) with bone lesions</td>
<td rowspan="2">Subcutaneous Dmab 120 mg plus intravenous placebo <italic>versus</italic> intravenous ZOL 4 mg plus subcutaneous PBO both arms every 4 weeks</td>
<td>Dmab was noninferior to ZOL in delaying first on-study SRE (HR = 0.84; <italic>p</italic> = 0.0007)</td>
</tr>
<tr>
<td>OS and disease progression were similar between groups</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr26-1756287212453079">Fizazi <italic>et al</italic>. [2011]</xref></td>
<td>1904</td>
<td>CRPC with bone metastases</td>
<td>Subcutaneous Dmab 120 mg plus intravenous PBO <italic>versus</italic> intravenous ZOL 4 mg plus subcutaneous PBO both arms every 4 weeks</td>
<td>Dmab ⬆median time to first on-study SRE (20.7 <italic>versus</italic> 17.1 months; <italic>p</italic> = 0.008)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1756287212453079">
<p>Data from <xref ref-type="bibr" rid="bibr66-1756287212453079">Saad <italic>et al</italic>. [2002</xref>, <xref ref-type="bibr" rid="bibr67-1756287212453079">2004</xref>], <xref ref-type="bibr" rid="bibr68-1756287212453079">Saad and Lipton [2005]</xref>, <xref ref-type="bibr" rid="bibr46-1756287212453079">Lipton <italic>et al</italic>. [2003]</xref>, <xref ref-type="bibr" rid="bibr84-1756287212453079">Zaghloul <italic>et al</italic>. [2010]</xref>, <xref ref-type="bibr" rid="bibr73-1756287212453079">Small <italic>et al</italic>. [2003]</xref>, <xref ref-type="bibr" rid="bibr24-1756287212453079">Ernst <italic>et al</italic>. [2003]</xref>, <xref ref-type="bibr" rid="bibr48-1756287212453079">Mason <italic>et al</italic>. [2007]</xref>, <xref ref-type="bibr" rid="bibr21-1756287212453079">Dearnaley <italic>et al</italic>. [2003</xref>, <xref ref-type="bibr" rid="bibr20-1756287212453079">2009]</xref>, <xref ref-type="bibr" rid="bibr27-1756287212453079">Fizazi <italic>et al</italic>. [2009</xref>, <xref ref-type="bibr" rid="bibr26-1756287212453079">2011</xref>], <xref ref-type="bibr" rid="bibr33-1756287212453079">Henry <italic>et al</italic>. [2011]</xref>.</p>
</fn>
<fn id="table-fn2-1756287212453079">
<p>BC, breast cancer; BP, bisphosphonate; CLO, clodronate; Dmab, denosumab; CRPC, castration-resistant prostate cancer; HR, hazard ratio; MM, multiple myeloma; NTX, N-telopeptide of type I collagen; OS, overall survival; PAM, pamidronate; PBO, placebo; PC, prostate cancer; PFS, progression-free survival; RCC, renal cell carcinoma; SMR, skeletal morbidity rate; SRE, skeletal-related event; ZOL, zoledronic acid.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Pooled data from two multicenter, randomized, placebo-controlled trials of pamidronate in patients with metastatic prostate cancer and bone pain demonstrated no significant treatment benefit as measured by reduction in SREs or palliation of bone pain [<xref ref-type="bibr" rid="bibr73-1756287212453079">Small <italic>et al</italic>. 2003</xref>]. In contrast, ZOL, a much more potent NBP than pamidronate, has demonstrated broad efficacy in the context of SRE prevention in patients with bone metastases from multiple tumor types, including GU malignancies [<xref ref-type="bibr" rid="bibr62-1756287212453079">Rosen <italic>et al</italic>. 2004</xref>; <xref ref-type="bibr" rid="bibr67-1756287212453079">Saad <italic>et al</italic>. 2004</xref>; <xref ref-type="bibr" rid="bibr68-1756287212453079">Saad and Lipton, 2005</xref>].</p>
<p>A placebo-controlled, randomized, phase 3 trial (<italic>N</italic> = 643) evaluating the efficacy of ZOL (4 mg intravenously over 15 min every 3 weeks) for prevention of SREs in patients with bone metastases from CRPC followed 122 patients for 24 months [<xref ref-type="bibr" rid="bibr67-1756287212453079">Saad <italic>et al</italic>. 2004</xref>]. The incidence of at least one SRE was significantly lower among patients receiving ZOL (38% <italic>versus</italic> 49%, <italic>p</italic> = 0.028). Treatment with ZOL resulted in a significant reduction in the ongoing risk of SREs by 36% (<italic>p</italic> = 0.002) and significantly reduced the median time to first SRE (488 days <italic>versus</italic> 321 days; <italic>p</italic> = 0.009) [<xref ref-type="bibr" rid="bibr67-1756287212453079">Saad <italic>et al</italic>. 2004</xref>]. The annual incidence of SREs was 0.77 for patients in the ZOL treatment group compared with 1.47 for the placebo group (<italic>p</italic> = 0.005) [<xref ref-type="bibr" rid="bibr67-1756287212453079">Saad <italic>et al</italic>. 2004</xref>]. In an exploratory analysis in 422 patients with CRPC, the effect of ZOL (4 mg every 3 weeks) on SRE incidence was stratified according to baseline pain status [<xref ref-type="bibr" rid="bibr65-1756287212453079">Saad and Eastham, 2010</xref>]. Among patients with baseline bone pain, ZOL reduced the proportion of patients with at least one SRE by 18% <italic>versus</italic> placebo, and by 39% in patients without pain at baseline.</p>
<p>A retrospective, subset analysis of patients with RCC (<italic>n</italic> = 74) enrolled in a single multicenter, prospective, placebo-controlled trial of ZOL for treatment of skeletal metastases from solid tumors has been reported at 9-month [<xref ref-type="bibr" rid="bibr46-1756287212453079">Lipton <italic>et al</italic>. 2003</xref>] and 21-month follow up [<xref ref-type="bibr" rid="bibr68-1756287212453079">Saad and Lipton, 2005</xref>]. The trial enrolled patients with a variety of solid tumors, including 74 patients with RCC [<xref ref-type="bibr" rid="bibr46-1756287212453079">Lipton <italic>et al</italic>. 2003</xref>]. At 9-month follow up, ZOL therapy significantly reduced the proportion of patients in this subset with an SRE (37% <italic>versus</italic> 74%; <italic>p</italic> = 0.015) and reduced the risk of developing an SRE by 61% compared with placebo [hazard ratio (HR) = 0.394; <italic>p</italic> = 0.008] [<xref ref-type="bibr" rid="bibr46-1756287212453079">Lipton <italic>et al</italic>. 2003</xref>]. The extended 21-month follow up of 46 patients in the RCC subset demonstrated continued benefit of ZOL with a significantly delayed time to first SRE by nearly 1 year and a significantly delayed time to disease progression compared with placebo (586 days for ZOL <italic>versus</italic> 89 days for placebo; <italic>p</italic> = 0.014) [<xref ref-type="bibr" rid="bibr68-1756287212453079">Saad and Lipton, 2005</xref>]. A retrospective survival analysis of patients with RCC enrolled in this same phase III study demonstrated that ZOL therapy was associated with a significant improvement in overall survival compared with placebo (11.4 <italic>versus</italic> 7.1 months, respectively; HR = 0.54; <italic>p</italic> = 0.014) [<xref ref-type="bibr" rid="bibr51-1756287212453079">Michaelson <italic>et al</italic>. 2010</xref>].</p>
<p>Additionally, a recent prospective, randomized, placebo-controlled trial has also confirmed the benefit of ZOL in patients with bladder cancer and bone metastases (<italic>N</italic> = 40) [<xref ref-type="bibr" rid="bibr84-1756287212453079">Zaghloul <italic>et al</italic>. 2010</xref>]. Patients treated with ZOL experienced a significantly reduced number of SREs by 54% (<italic>p</italic> = 0.001), prolonged time to first on-study SRE (<italic>p</italic> = 0.0001), and decreased bone pain scores compared with placebo (<italic>p</italic> = 0.015). Notably, there was a significantly increased 1-year survival rate for patients in the ZOL treatment group (36.3% <italic>versus</italic> 0% for placebo; <italic>p</italic> = 0.004). These studies demonstrate consistent reduction and delay in the development of SREs for patients with GU malignancies who are treated with ZOL.</p>
<p>Recently, Dmab achieved noninferiority <italic>versus</italic> ZOL in delaying the time to first on-study SRE (20.6 <italic>versus</italic> 16.3 months, respectively) in patients with bone metastases from solid tumors (excluding breast and prostate cancer) or multiple myeloma (<italic>N</italic> = 1776; HR = 0.84; 95% confidence interval [CI] 0.71–0.98; <italic>p</italic> = 0.0007) [<xref ref-type="bibr" rid="bibr33-1756287212453079">Henry <italic>et al</italic>. 2011</xref>]. It is important to note that the patient population in this trial included only 218 (12%) patients with GU cancers (<italic>n</italic> = 155 for RCC; <italic>n</italic> = 63 for bladder cancer) [<xref ref-type="bibr" rid="bibr34-1756287212453079">Henry <italic>et al</italic>. 2009</xref>]. However, <italic>post hoc</italic> analyses by tumor type, although underpowered for statistical analyses, demonstrated similar benefits with Dmab for delaying first on-study SRE in patients with renal, colorectal, or bladder cancer as in the overall trial population [<xref ref-type="bibr" rid="bibr34-1756287212453079">Henry <italic>et al</italic>. 2009</xref>]. In the overall population, Dmab was neither statistically superior to ZOL in time to first on-study SRE (<italic>p</italic> = 0.06) nor in time to first and subsequent (multiple) SREs (<italic>p</italic> = 0.14) [<xref ref-type="bibr" rid="bibr33-1756287212453079">Henry <italic>et al</italic>. 2011</xref>]. Overall survival and disease progression were similar for both treatment groups as well. A second double-blind, randomized, phase III trial compared Dmab and ZOL in 1904 patients with CRPC. The median time to first on-study SRE was significantly longer in the patients receiving Dmab compared with those in the ZOL treatment group (20.7 <italic>versus</italic> 17.1 months, respectively; <italic>p</italic> = 0.008) [<xref ref-type="bibr" rid="bibr26-1756287212453079">Fizazi <italic>et al</italic>. 2011</xref>].</p>
<p>In addition to reduction of SRE risk, antiresorptive agents have been shown to reduce bone pain. Patients with CRPC receiving treatment with ZOL had a significant reduction in composite Brief Pain Inventory (BPI) score compared with placebo-treated patients at 2 years (<italic>p</italic> = 0.024) [<xref ref-type="bibr" rid="bibr67-1756287212453079">Saad <italic>et al</italic>. 2004</xref>]. Visual analog scale (VAS) scores for pain were significantly reduced in another trial of ZOL therapy in patients with solid tumors, including prostate cancer (<italic>p</italic> &lt; 0.05) [<xref ref-type="bibr" rid="bibr78-1756287212453079">Vogel <italic>et al</italic>. 2004</xref>]. An open-label study of ZOL evaluated the safety and efficacy in patients with a variety of malignancies, including GU cancers, over the course of 12 ZOL (4 mg) infusions administered every 3 or 4 weeks. Mean VAS scores decreased significantly by 13.9 ± 32.3 (<italic>p</italic> &lt; 0.0001), and mean analgesic scores decreased by 0.56 ± 1.42 (<italic>p</italic> &lt; 0.0001) [<xref ref-type="bibr" rid="bibr44-1756287212453079">Kretzschmar <italic>et al</italic>. 2007</xref>]. Recent evidence from analysis of phase III data comparing ZOL and Dmab demonstrated similar benefits for both treatments in patients with CRPC and bone pain [<xref ref-type="bibr" rid="bibr61-1756287212453079">Patrick <italic>et al</italic>. 2011</xref>]. The proportion of patients with decreased pain interference of general activity declined over 18 months, and treatment prolonged the time to worsening of pain interference for patients in both treatment arms. These studies highlight the clinical benefit associated with prevention of abnormal bone resorption in patients with metastatic bone disease. Both ZOL and Dmab have been shown to reduce bone pain and significantly reduce the incidence of SREs in patients with GU malignancies.</p>
</sec>
<sec id="section5-1756287212453079">
<title>Tolerability profiles of antiresorptive agents</title>
<p>Antiresorptive therapies are generally well tolerated, particularly with close adherence to established guidelines for drug administration and adverse event (AE) management. ZOL has a long-term, well defined safety profile [<xref ref-type="bibr" rid="bibr66-1756287212453079">Saad <italic>et al</italic>. 2002</xref>, <xref ref-type="bibr" rid="bibr67-1756287212453079">2004</xref>; <xref ref-type="bibr" rid="bibr2-1756287212453079">Aapro and Saad, 2012</xref>] with well established protocols regarding AE management [<xref ref-type="bibr" rid="bibr88-1756287212453079">Zometa PI, 2011</xref>]. In contrast, because it is a newer antiresorptive agent, the long-term safety profile for Dmab has yet to be established [<xref ref-type="bibr" rid="bibr82-1756287212453079">Xgeva PI, 2010</xref>]. However, in the phase III trials of Dmab <italic>versus</italic> ZOL, total AEs and serious AEs were similar between treatment arms and both agents were well tolerated [<xref ref-type="bibr" rid="bibr26-1756287212453079">Fizazi <italic>et al</italic>. 2011</xref>; <xref ref-type="bibr" rid="bibr33-1756287212453079">Henry <italic>et al</italic>. 2011</xref>].</p>
<p>Osteonecrosis of the jaw (ONJ), renal toxicity, hypocalcemia, and acute phase reactions (APRs) are AEs of interest that have been reported in patients receiving antiresorptive therapies. Rates of renal AEs and ONJ were also similar for Dmab and ZOL. Indeed, the incidence of ONJ was uncommon and was reported at similar rates in phase III trials comparing Dmab with ZOL (1–2%) in patients with advanced cancer [<xref ref-type="bibr" rid="bibr26-1756287212453079">Fizazi <italic>et al</italic>. 2011</xref>; <xref ref-type="bibr" rid="bibr33-1756287212453079">Henry <italic>et al</italic>. 2011</xref>]. AEs potentially associated with renal impairment were similar in patients with CRPC receiving Dmab (15%) compared with ZOL (16%) [<xref ref-type="bibr" rid="bibr26-1756287212453079">Fizazi <italic>et al</italic>. 2011</xref>]. Moreover, renal AEs also were similar across treatment arms in patients with solid tumors (excluding breast or prostate cancer) or multiple myeloma (8% Dmab <italic>versus</italic> 11% ZOL; <italic>p</italic> = 0.07) [<xref ref-type="bibr" rid="bibr33-1756287212453079">Henry <italic>et al</italic>. 2011</xref>].</p>
<p>Hypocalcemia and APR AEs were notably different for Dmab compared with ZOL [<xref ref-type="bibr" rid="bibr26-1756287212453079">Fizazi <italic>et al</italic>. 2011</xref>; <xref ref-type="bibr" rid="bibr33-1756287212453079">Henry <italic>et al</italic>. 2011</xref>]. Indeed, hypocalcemia was significantly more common in patients receiving Dmab compared with ZOL (11–13% <italic>versus</italic> 6%, respectively; <italic>p</italic> &lt; 0.0001) [<xref ref-type="bibr" rid="bibr26-1756287212453079">Fizazi <italic>et al</italic>. 2011</xref>; <xref ref-type="bibr" rid="bibr33-1756287212453079">Henry <italic>et al</italic>. 2011</xref>]. Notably, monitoring serum calcium to assess hypocalcemia for patients receiving Dmab is indicated in the Dmab prescribing information [<xref ref-type="bibr" rid="bibr82-1756287212453079">Xgeva PI, 2010</xref>]. Furthermore, AEs related to APR occurred less frequently in patients receiving Dmab (7–8%) compared with ZOL (15–18%) [<xref ref-type="bibr" rid="bibr26-1756287212453079">Fizazi <italic>et al</italic>. 2011</xref>; <xref ref-type="bibr" rid="bibr33-1756287212453079">Henry <italic>et al</italic>. 2011</xref>]. Generally, APR AEs are easily managed with analgesics, and prophylactic use of acetaminophen can reduce the incidence and severity of these events [<xref ref-type="bibr" rid="bibr76-1756287212453079">Tanvetyanon and Stiff, 2006</xref>; <xref ref-type="bibr" rid="bibr1-1756287212453079">Aapro <italic>et al</italic>. 2008</xref>]. Furthermore, APRs are generally mild and reversible and either do not manifest in subsequent cycles of therapy or are of reduced severity [<xref ref-type="bibr" rid="bibr50-1756287212453079">Maxwell <italic>et al</italic>. 2003</xref>].</p>
</sec>
<sec id="section6-1756287212453079">
<title>Use of bone turnover markers to optimize treatment</title>
<p>The use of bone turnover markers has been suggested as a way to further optimize and define treatment outcomes for the antiresorptive agents. Given their differing mechanisms of action, there may be differences in physiological effect beyond prevention of SREs that occurs with ZOL or Dmab therapy. Studies suggest that elevated bone turnover markers may be associated with a greater risk of SREs and reduced survival duration [<xref ref-type="bibr" rid="bibr7-1756287212453079">Brown <italic>et al</italic>. 2005</xref>; <xref ref-type="bibr" rid="bibr16-1756287212453079">Cook <italic>et al</italic>. 2006</xref>; <xref ref-type="bibr" rid="bibr69-1756287212453079">Saad <italic>et al</italic>. 2007</xref>]. For example, a marker of bone metabolism, N-telopeptide of type I collagen (NTX), which is a marker of osteoclast-mediated bone resorption, has been identified and provides a useful surrogate measure for monitoring skeletal health in patients with bone metastases [<xref ref-type="bibr" rid="bibr15-1756287212453079">Coleman <italic>et al</italic>. 2005</xref>, <xref ref-type="bibr" rid="bibr14-1756287212453079">2011</xref>]. In an exploratory analysis of data from three separate phase III trials of ZOL in patients with bone metastases, 61% (193/314) of patients with CRPC had elevated NTX levels at baseline [<xref ref-type="bibr" rid="bibr45-1756287212453079">Lipton <italic>et al</italic>. 2008</xref>]. Normalization of NTX after 3 months of ZOL therapy correlated with a 59% reduced risk of death [relative risk (RR) = 0.41; 95% CI 0.29–0.59; <italic>p</italic> &lt; 0.0001] (<xref ref-type="fig" rid="fig1-1756287212453079">Figure 1</xref>), a nonsignificant 29% reduced rate of first fracture (<italic>p</italic> = 0.3653), and a 49% increase in SRE-free survival (<italic>p</italic> = 0.0009) compared with patients with persistently elevated NTX levels [<xref ref-type="bibr" rid="bibr45-1756287212453079">Lipton <italic>et al</italic>. 2008</xref>]. In a study of patients with prostate cancer undergoing hormonal therapy it was reported that elevated levels of bone turnover markers correlate with recurrence and progression of bone metastases [<xref ref-type="bibr" rid="bibr58-1756287212453079">Noguchi <italic>et al</italic>. 2003</xref>]. Thus, bone turnover markers may have utility for assessing response to treatment in patients with bone metastases, including overall tumor response. In fact, in a recent study of patients with prostate cancer metastatic to bone undergoing ZOL treatment, overall survival was longer in patients whose bone turnover marker levels decreased within 3 months [<xref ref-type="bibr" rid="bibr36-1756287212453079">Izumi <italic>et al</italic>. 2012</xref>].</p>
<fig id="fig1-1756287212453079" position="float">
<label>Figure 1.</label>
<caption>
<p>Kaplan–Meier survival estimates stratified by baseline and 3-month N-telopeptide of type I collagen (NTX) levels. Patients with bone metastases from hormone-refractory prostate cancer treated with zoledronic acid. E-E, patients with elevated baseline and 3-month NTX; E-N, patients with elevated baseline and normalized 3-month NTX; N, patients with normal baseline NTX. Reprinted with permission from <xref ref-type="bibr" rid="bibr45-1756287212453079">Lipton <italic>et al</italic>. [2008]</xref>.</p>
</caption>
<graphic xlink:href="10.1177_1756287212453079-fig1.tif"/>
</fig>
<p>Denosumab therapy is also associated with reduced NTX levels that correlate with fewer on-study SREs [<xref ref-type="bibr" rid="bibr27-1756287212453079">Fizazi <italic>et al</italic>. 2009</xref>, <xref ref-type="bibr" rid="bibr26-1756287212453079">2011</xref>]. In the phase III trial comparing Dmab with ZOL for treatment of bone metastases in CRPC, Dmab was associated with significantly greater reductions in NTX and bone-specific alkaline phosphatase compared with ZOL [<xref ref-type="bibr" rid="bibr26-1756287212453079">Fizazi <italic>et al</italic>. 2011</xref>]. However, both agents reduced bone turnover marker levels, and there was no difference between Dmab and ZOL in time to disease progression (HR = 1.06, <italic>p</italic> = 0.30) or overall survival (HR = 1.03, <italic>p</italic> = 0.65) [<xref ref-type="bibr" rid="bibr26-1756287212453079">Fizazi <italic>et al</italic>. 2011</xref>]. Survival was not analyzed according to bone turnover marker response. Another study that evaluated the effect of Dmab on BMD and turnover markers in postmenopausal women with low bone density observed a reversal of effect on BMD and turnover makers such that levels of bone alkaline phosphatase and NTX increased above baseline levels after discontinuation of Dmab [<xref ref-type="bibr" rid="bibr52-1756287212453079">Miller <italic>et al</italic>. 2008</xref>]. Further research regarding the correlation of bone turnover marker levels with anticancer and bone disease outcomes from antiresorptive therapies will aid in understanding differences between the current antiresorptive agents.</p>
</sec>
<sec id="section7-1756287212453079">
<title>Evidence for the potential anticancer benefits of antiresorptive agents</title>
<p>In preclinical and clinical studies in patients with advanced cancer, BPs have been shown to elicit a variety of anticancer responses from direct effects on tumor cell survival and proliferation to indirect antitumor effects mediated by their modulation of angiogenesis, host immunosurveillance, and inhibition of tumor-promoting processes in the bone microenvironment [<xref ref-type="bibr" rid="bibr83-1756287212453079">Yuasa <italic>et al</italic>. 2007</xref>; <xref ref-type="bibr" rid="bibr11-1756287212453079">Clezardin, 2011</xref>]. In general, antiresorptive agents inhibit a broad range of cellular functions, including cell differentiation, which is particularly relevant in the context of osteoclast activity and may provide important anticancer effects as well. For example, the NBP-mediated inhibition of farnesyl pyrophosphate synthase also causes accumulation of isopentenyl-pyrophosphate (IPP) that has been shown to activate γδ T cells. The γδ T cells are a subset of the peripheral blood T cells that play a role in tumor-specific immunity. Cytotoxic activity of γδ T cells toward a range of malignant cell types, including bladder cancer, has been demonstrated <italic>in vitro</italic> [<xref ref-type="bibr" rid="bibr38-1756287212453079">Kato <italic>et al</italic>. 2001</xref>].</p>
<p>Zoledronic acid is a potent inducer of γδ T-cell proliferation, which may in part account for ZOL-induced anticancer effects [<xref ref-type="bibr" rid="bibr47-1756287212453079">Mariani <italic>et al</italic>. 2005</xref>]. Two small studies in patients with prostate cancer have shown that ZOL activates and increases the number of γδ T cells [<xref ref-type="bibr" rid="bibr22-1756287212453079">Dieli <italic>et al</italic>. 2007</xref>; <xref ref-type="bibr" rid="bibr55-1756287212453079">Naoe <italic>et al</italic>. 2010</xref>], and in one of the studies ZOL treatment was associated with a reduction in prostate-specific antigen (PSA) velocity in 50% (5/10) of the patients [<xref ref-type="bibr" rid="bibr55-1756287212453079">Naoe <italic>et al</italic>. 2010</xref>]. Interestingly, activation of γδ T cells after ZOL treatment alone was also associated with reduced PSA velocity in two patients [<xref ref-type="bibr" rid="bibr55-1756287212453079">Naoe <italic>et al</italic>. 2010</xref>]. These studies further suggest that ZOL combined with interleukin-2 may offer further benefit in terms of γδ T-cell proliferation and immunotherapy effect.</p>
<p>In addition to immunomodulatory effects, data suggest that NBPs may inhibit tumor-mediated angiogenesis and render the bone microenvironment less conducive to growth of micrometastases [<xref ref-type="bibr" rid="bibr80-1756287212453079">Wood <italic>et al</italic>. 2002</xref>]. The effect of NBPs on angiogenesis and neovascularization is presumed to be related to inhibition of angiogenic factors [eg, vascular endothelial growth factor, platelet-derived growth factor, basic fibroblast growth factor (bFGF)] necessary for proliferation of endothelial cells [<xref ref-type="bibr" rid="bibr80-1756287212453079">Wood <italic>et al</italic>. 2002</xref>]. Furthermore, ZOL has been shown to modulate cellular adhesion and migration and inhibit angiogenesis induced by subcutaneous implants containing bFGF <italic>in vivo</italic> [<xref ref-type="bibr" rid="bibr80-1756287212453079">Wood <italic>et al</italic>. 2002</xref>]. The effects of NBPs on the bone microenvironment, angiogenesis, and stimulation of immune surveillance via γδ T-cell proliferation suggest the potential of these agents for additional anticancer benefits.</p>
<p>In addition to indirect effects, preclinical studies have shown direct anticancer activity of ZOL in RCC cell lines. Indeed, ZOL treatment induced apoptosis in several RCC cell lines [<xref ref-type="bibr" rid="bibr60-1756287212453079">Pandha <italic>et al</italic>. 2006</xref>; <xref ref-type="bibr" rid="bibr77-1756287212453079">Ullen <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr89-1756287212453079">Zwolak <italic>et al</italic>. 2010</xref>]. Furthermore, a single case study in which lung and bone metastases displayed remission after BP therapy and a small retrospective analysis demonstrating improved objective response rate with ZOL therapy add support for the potential direct anticancer effects of ZOL in RCC [<xref ref-type="bibr" rid="bibr41-1756287212453079">Kijima <italic>et al</italic>. 2008</xref>, <xref ref-type="bibr" rid="bibr40-1756287212453079">2009</xref>].</p>
<p>The potential anticancer activity of ZOL has also been observed when used in combination with traditional anticancer agents. A number of studies have demonstrated an additive or synergistic effect of ZOL with chemotherapy against leukemias and solid tumors [<xref ref-type="bibr" rid="bibr43-1756287212453079">Kimura <italic>et al</italic>. 2004</xref>; <xref ref-type="bibr" rid="bibr49-1756287212453079">Matsumoto <italic>et al</italic>. 2005</xref>; <xref ref-type="bibr" rid="bibr57-1756287212453079">Neville-Webbe <italic>et al</italic>. 2005</xref>, <xref ref-type="bibr" rid="bibr56-1756287212453079">2006</xref>, <xref ref-type="bibr" rid="bibr70-1756287212453079">Sato <italic>et al</italic>. 2006</xref>]. The combination of an NBP (minodronic acid) with cisplatin or paclitaxel has been shown to kill bladder cancer cells in culture and has inhibited growth of bone metastases <italic>in vivo</italic> in a bladder cancer mouse model [<xref ref-type="bibr" rid="bibr70-1756287212453079">Sato <italic>et al</italic>. 2006</xref>]. Doxorubicin-induced apoptosis has also been shown to be synergistically enhanced by the use of ZOL in breast and prostate cancer cells [<xref ref-type="bibr" rid="bibr57-1756287212453079">Neville-Webbe <italic>et al</italic>. 2005</xref>]. This study highlights the importance of drug sequence when adding ZOL for treatment of malignant cells, as apoptosis was only enhanced by the use of ZOL after treatment by doxorubicin. There is also evidence for an additive anticancer effect of ZOL when combined with endocrine therapy. Long-term follow up of a trial comparing adjuvant endocrine therapy with or without ZOL has recently demonstrated that the addition of ZOL improved disease-free survival of patients with early-stage breast cancer (92% <italic>versus</italic> 88%, log-rank <italic>p</italic> = 0.008) [<xref ref-type="bibr" rid="bibr30-1756287212453079">Gnant <italic>et al</italic>. 2011</xref>].</p>
<p>Circulating tumor cells (CTCs) have not been extensively explored in GU malignancies; however, data from other solid tumors suggest that CTCs are associated with a worse prognosis and that reducing CTC numbers may be associated with reduced risk of recurrent/progressive disease [<xref ref-type="bibr" rid="bibr17-1756287212453079">Cristofanilli <italic>et al</italic>. 2004</xref>, <xref ref-type="bibr" rid="bibr18-1756287212453079">2005</xref>; <xref ref-type="bibr" rid="bibr8-1756287212453079">Budd <italic>et al</italic>. 2006</xref>; <xref ref-type="bibr" rid="bibr32-1756287212453079">Hayes <italic>et al</italic>. 2006</xref>; <xref ref-type="bibr" rid="bibr37-1756287212453079">Janni <italic>et al</italic>. 2011</xref>]. Two studies in metastatic prostate cancer have demonstrated a correlation between greater numbers of CTCs, elevated serum PSA, and poor overall survival (<xref ref-type="fig" rid="fig2-1756287212453079">Figure 2</xref>) [<xref ref-type="bibr" rid="bibr54-1756287212453079">Moreno <italic>et al</italic>. 2005</xref>; <xref ref-type="bibr" rid="bibr28-1756287212453079">Garcia <italic>et al</italic>. 2007</xref>]. Another study evaluating CTCs in relation to disease spread and outcome in patients with CRPC found that the baseline CTC number was strongly correlated with survival, and that the predictive value increased when baseline PSA and serum albumin were included in the analysis. Higher numbers of CTCs were observed in patients with bone metastases compared with other sites of metastases [<xref ref-type="bibr" rid="bibr19-1756287212453079">Danila <italic>et al</italic>. 2007</xref>]. Most recently, research in patients with metastatic CRPC receiving chemotherapy showed that CTCs and lactate dehydrogenase levels may be useful as surrogate markers for overall survival [<xref ref-type="bibr" rid="bibr71-1756287212453079">Scher <italic>et al</italic>. 2011</xref>]. ZOL has previously been shown to reduce CTC numbers in patients with cancer, suggesting another mechanism by which ZOL may potentially improve overall outcomes in patients with GU malignancies [<xref ref-type="bibr" rid="bibr75-1756287212453079">Solomayer <italic>et al</italic>. 2012</xref>; <xref ref-type="bibr" rid="bibr3-1756287212453079">Aft <italic>et al</italic>. 2010</xref>]. These observations of a potential direct anticancer effect from ZOL have not been reported with Dmab, indicating important differences in the pharmacologic effects of these agents that are likely based on their different mechanisms of action and pharmacokinetic profiles.</p>
<fig id="fig2-1756287212453079" position="float">
<label>Figure 2.</label>
<caption>
<p>(a) Probability of overall survival time in the subset of patients with CRPC (<italic>n</italic> = 26) for those with less than 5 CTCs/7.5 ml blood (solid line) and 5 or more CTCs/7.5 ml blood (dotted line). Reprinted with permission from <xref ref-type="bibr" rid="bibr54-1756287212453079">Moreno <italic>et al</italic>. [2005]</xref>. (b) Overall survival versus CECs/ml in patients with CRPC. Reprinted with permission from <xref ref-type="bibr" rid="bibr28-1756287212453079">Garcia <italic>et al</italic>. [2007]</xref>. CEC, circulating epithelial cell; CRPC, castration-resistant prostate cancer; CTC, circulating tumor cell.</p>
</caption>
<graphic xlink:href="10.1177_1756287212453079-fig2.tif"/>
</fig>
<p>To date, there is no clinical evidence of anticancer effects with Dmab; however, preclinical studies with inhibitors of RANKL signaling (which may mimic Dmab effects) have been conducted. Potential mechanisms of anticancer effects from Dmab are related to the role of RANK, RANKL, and endogenous osteoprotegerin (OPG), a surrogate for Dmab activity in animal studies, in regulation of osteoclastogenesis and bone resorption [<xref ref-type="bibr" rid="bibr79-1756287212453079">Wada <italic>et al</italic>. 2006</xref>]. While it has been shown that OPG binding to RANKL prevents the osteolytic action of prostate cancer [<xref ref-type="bibr" rid="bibr86-1756287212453079">Zhang <italic>et al</italic>. 2001</xref>], OPG can prevent tumor necrosis factor-related apoptosis-induced ligand (TRAIL)-mediated apoptosis [<xref ref-type="bibr" rid="bibr35-1756287212453079">Holen <italic>et al</italic>. 2002</xref>]. In contrast, the soluble receptor activator of nuclear factor κB (sRANK) inhibited RANKL in a mouse model but did not prevent TRAIL-induced apoptosis and did reduce prostate tumor cell growth [<xref ref-type="bibr" rid="bibr87-1756287212453079">Zhang <italic>et al</italic>. 2003</xref>]. These data suggest that inhibition of RANKL by molecules that do not interact with TRAIL may prevent metastatic cancer progression in bone. However, a preclinical study showed that Dmab could not induce apoptosis or inhibit proliferation of a breast cancer cell line (MCF-7), but that ZOL could [<xref ref-type="bibr" rid="bibr23-1756287212453079">Ebert <italic>et al</italic>. 2011</xref>]. Moreover, based on the mechanism of Dmab’s antiresorptive effect, an immune-mediated anticancer response to Dmab therapy is unlikely, and there have been concerns regarding increased immunosuppression resulting from RANKL inhibition because, in addition to expression on osteoclasts, RANKL is expressed on T and B cells of the immune system [<xref ref-type="bibr" rid="bibr39-1756287212453079">Kawai <italic>et al</italic>. 2006</xref>; <xref ref-type="bibr" rid="bibr4-1756287212453079">Benzaïd <italic>et al</italic>. 2011</xref>]. Indeed, a preclinical study has shown that Dmab does not induce γδ T-cell expansion in a breast cancer model [<xref ref-type="bibr" rid="bibr4-1756287212453079">Benzaïd <italic>et al</italic>. 2011</xref>].</p>
<p>Although there is no clinical evidence for antitumor activity associated with Dmab, a clinical trial to assess the potential of Dmab to prevent bone metastases in patients with prostate cancer and at high risk for development of bone metastases has recently been presented [<xref ref-type="bibr" rid="bibr59-1756287212453079">Oudard <italic>et al</italic>. 2011</xref>; <xref ref-type="bibr" rid="bibr74-1756287212453079">Smith <italic>et al</italic>. 2012</xref>]. In this phase III trial in patients with CRPC at high risk for bone metastases (<italic>N</italic> = 1432), Dmab (120 mg every 4 weeks) significantly prolonged bone-metastases-free survival by 4.3 months <italic>versus</italic> placebo (29.5 <italic>versus</italic> 25.2 months, respectively; HR = 0.85, <italic>p</italic> = 0.028) [<xref ref-type="bibr" rid="bibr59-1756287212453079">Oudard <italic>et al</italic>. 2011</xref>; <xref ref-type="bibr" rid="bibr74-1756287212453079">Smith <italic>et al</italic>. 2012</xref>]. However, Dmab did not prolong progression-free (HR = 0.89, <italic>p</italic> = 0.093) or overall survival (HR = 1.01, <italic>p</italic> = 0.91) <italic>versus</italic> placebo [<xref ref-type="bibr" rid="bibr59-1756287212453079">Oudard <italic>et al</italic>. 2011</xref>; <xref ref-type="bibr" rid="bibr74-1756287212453079">Smith <italic>et al</italic>. 2012</xref>].</p>
</sec>
<sec id="section8-1756287212453079" sec-type="conclusions">
<title>Conclusions</title>
<p>Questions remain regarding the optimal duration and dosing of antiresorptive therapies to prevent or palliate SREs. Bone turnover markers such as NTX may be useful surrogates to monitor therapeutic effects on bone and help guide future trials. Furthermore, assessment of circulating angiogenic markers and CTCs may provide greater insight into the anticancer activity of antiresorptive therapies. Currently, three large trials are ongoing in patients with prostate cancer to evaluate the effect of ZOL on event-free and overall survival [<xref ref-type="bibr" rid="bibr14-1756287212453079">Coleman <italic>et al</italic>. 2011</xref>].</p>
<p>Clinical trials of antiresorptive agents confirm the value of this therapy in prevention of potentially debilitating and life-limiting SREs, and provide evidence for a further role in delaying disease progression and prolonging survival in some cases. The potential for synergistic benefit with combined chemotherapy or androgen therapy plus ZOL in GU malignancies is encouraging, and future trials are anticipated.</p>
</sec>
</body>
<back>
<ack>
<p>I thank Colleen Gilbert, PhD, ProEd Communications, Inc., for her medical editorial assistance with this manuscript.</p>
</ack>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>Financial support for medical editorial assistance was provided by Novartis Pharmaceuticals Corporation. No additional funding was provided.</p>
</fn>
<fn fn-type="conflict">
<label>Conflict of interest statement</label>
<p>None declared.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Aapro</surname><given-names>M.</given-names></name>
<name><surname>Abrahamsson</surname><given-names>P.</given-names></name>
<name><surname>Body</surname><given-names>J.</given-names></name>
<name><surname>Coleman</surname><given-names>R.</given-names></name>
<name><surname>Colomer</surname><given-names>R.</given-names></name>
<name><surname>Costa</surname><given-names>L.</given-names></name>
<etal/>
</person-group>. (<year>2008</year>) <article-title>Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel</article-title>. <source>Ann Oncol</source> <volume>19</volume>: <fpage>420</fpage>–<lpage>432</lpage>.</citation>
</ref>
<ref id="bibr2-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Aapro</surname><given-names>M.</given-names></name>
<name><surname>Saad</surname><given-names>F.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid</article-title>. <source>Ther Adv Urol</source> <volume>4</volume>: <fpage>85</fpage>–<lpage>101</lpage>.</citation>
</ref>
<ref id="bibr3-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Aft</surname><given-names>R.</given-names></name>
<name><surname>Naughton</surname><given-names>M.</given-names></name>
<name><surname>Trinkaus</surname><given-names>K.</given-names></name>
<name><surname>Watson</surname><given-names>M.</given-names></name>
<name><surname>Ylagan</surname><given-names>L.</given-names></name>
<name><surname>Chavez-Macgregor</surname><given-names>M.</given-names></name>
<etal/>
</person-group>. (<year>2010</year>) <article-title>Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial</article-title>. <source>Lancet Oncol</source> <volume>11</volume>: <fpage>421</fpage>–<lpage>428</lpage>.</citation>
</ref>
<ref id="bibr4-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Benzaïd</surname><given-names>I.</given-names></name>
<name><surname>Mönkkönen</surname><given-names>H.</given-names></name>
<name><surname>Clézardin</surname><given-names>P.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Effects of zoledronic acid and denosumab on human Vγ9Vδ2 T-cell-mediated cell death of RANK-expressing breast cancer cells</article-title>. <source>Eur J Cancer</source> <volume>47</volume>: <fpage>S117</fpage>.</citation>
</ref>
<ref id="bibr5-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Body</surname><given-names>J.</given-names></name>
<name><surname>Facon</surname><given-names>T.</given-names></name>
<name><surname>Coleman</surname><given-names>R.</given-names></name>
<name><surname>Lipton</surname><given-names>A.</given-names></name>
<name><surname>Geurs</surname><given-names>F.</given-names></name>
<name><surname>Fan</surname><given-names>M.</given-names></name>
<etal/>
</person-group>. (<year>2006</year>) <article-title>A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer</article-title>. <source>Clin Cancer Res</source> <volume>12</volume>: <fpage>1221</fpage>–<lpage>1228</lpage>.</citation>
</ref>
<ref id="bibr6-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bouganim</surname><given-names>N.</given-names></name>
<name><surname>Dranitsaris</surname><given-names>G.</given-names></name>
<name><surname>Amir</surname><given-names>E.</given-names></name>
<name><surname>Clemons</surname><given-names>M.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Optimising the use of bone-targeted agents in patients with metastatic cancers: a practical guide for medical oncologists</article-title>. <source>Support Care Cancer</source> <volume>19</volume>: <fpage>1687</fpage>–<lpage>1696</lpage>.</citation>
</ref>
<ref id="bibr7-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brown</surname><given-names>J.</given-names></name>
<name><surname>Cook</surname><given-names>R.</given-names></name>
<name><surname>Major</surname><given-names>P.</given-names></name>
<name><surname>Lipton</surname><given-names>A.</given-names></name>
<name><surname>Saad</surname><given-names>F.</given-names></name>
<name><surname>Smith</surname><given-names>M.</given-names></name>
<etal/>
</person-group>. (<year>2005</year>) <article-title>Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors</article-title>. <source>J Natl Cancer Inst</source> <volume>97</volume>: <fpage>59</fpage>–<lpage>69</lpage>.</citation>
</ref>
<ref id="bibr8-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Budd</surname><given-names>G.</given-names></name>
<name><surname>Cristofanilli</surname><given-names>M.</given-names></name>
<name><surname>Ellis</surname><given-names>M.</given-names></name>
<name><surname>Stopeck</surname><given-names>A.</given-names></name>
<name><surname>Borden</surname><given-names>E.</given-names></name>
<name><surname>Miller</surname><given-names>M.</given-names></name>
<etal/>
</person-group>. (<year>2006</year>) <article-title>Circulating tumor cells versus imaging–predicting overall survival in metastatic breast cancer</article-title>. <source>Clin Cancer Res</source> <volume>12</volume>: <fpage>6403</fpage>–<lpage>6409</lpage>.</citation>
</ref>
<ref id="bibr9-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Castellano</surname><given-names>D.</given-names></name>
<name><surname>Sepulveda</surname><given-names>J.</given-names></name>
<name><surname>Garcia-Escobar</surname><given-names>I.</given-names></name>
<name><surname>Rodriguez-Antolin</surname><given-names>A.</given-names></name>
<name><surname>Sundlov</surname><given-names>A.</given-names></name>
<name><surname>Cortes-Funes</surname><given-names>H.</given-names></name>
</person-group> (<year>2011</year>) <article-title>The role of RANK-ligand inhibition in cancer: the story of denosumab</article-title>. <source>Oncologist</source> <volume>16</volume>: <fpage>136</fpage>–<lpage>145</lpage>.</citation>
</ref>
<ref id="bibr10-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname><given-names>T.</given-names></name>
<name><surname>Berenson</surname><given-names>J.</given-names></name>
<name><surname>Vescio</surname><given-names>R.</given-names></name>
<name><surname>Swift</surname><given-names>R.</given-names></name>
<name><surname>Gilchick</surname><given-names>A.</given-names></name>
<name><surname>Goodin</surname><given-names>S.</given-names></name>
<etal/>
</person-group>. (<year>2002</year>) <article-title>Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases</article-title>. <source>J Clin Pharmacol</source> <volume>42</volume>: <fpage>1228</fpage>–<lpage>1236</lpage>.</citation>
</ref>
<ref id="bibr11-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Clezardin</surname><given-names>P.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Bisphosphonates’ antitumor activity: an unravelled side of a multifaceted drug class</article-title>. <source>Bone</source> <volume>48</volume>: <fpage>71</fpage>–<lpage>79</lpage>.</citation>
</ref>
<ref id="bibr12-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Coleman</surname><given-names>R.</given-names></name>
</person-group> (<year>1997</year>) <article-title>Skeletal complications of malignancy</article-title>. <source>Cancer</source> <volume>80</volume>: <fpage>1588</fpage>–<lpage>1594</lpage>.</citation>
</ref>
<ref id="bibr13-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Coleman</surname><given-names>R.</given-names></name>
</person-group> (<year>2001</year>) <article-title>Metastatic bone disease: clinical features, pathophysiology and treatment strategies</article-title>. <source>Cancer Treat Rev</source> <volume>27</volume>: <fpage>165</fpage>–<lpage>176</lpage>.</citation>
</ref>
<ref id="bibr14-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Coleman</surname><given-names>R.</given-names></name>
<name><surname>Cook</surname><given-names>R.</given-names></name>
<name><surname>Hirsh</surname><given-names>V.</given-names></name>
<name><surname>Major</surname><given-names>P.</given-names></name>
<name><surname>Lipton</surname><given-names>A.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Zoledronic acid use in cancer patients: more than just supportive care?</article-title> <source>Cancer</source> <volume>117</volume>: <fpage>11</fpage>–<lpage>23</lpage>.</citation>
</ref>
<ref id="bibr15-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Coleman</surname><given-names>R.</given-names></name>
<name><surname>Major</surname><given-names>P.</given-names></name>
<name><surname>Lipton</surname><given-names>A.</given-names></name>
<name><surname>Brown</surname><given-names>J.</given-names></name>
<name><surname>Lee</surname><given-names>K.</given-names></name>
<name><surname>Smith</surname><given-names>M.</given-names></name>
<etal/>
</person-group>. (<year>2005</year>) <article-title>Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid</article-title>. <source>J Clin Oncol</source> <volume>23</volume>: <fpage>4925</fpage>–<lpage>4935</lpage>.</citation>
</ref>
<ref id="bibr16-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cook</surname><given-names>R.</given-names></name>
<name><surname>Coleman</surname><given-names>R.</given-names></name>
<name><surname>Brown</surname><given-names>J.</given-names></name>
<name><surname>Lipton</surname><given-names>A.</given-names></name>
<name><surname>Major</surname><given-names>P.</given-names></name>
<name><surname>Hei</surname><given-names>Y.</given-names></name>
<etal/>
</person-group>. (<year>2006</year>) <article-title>Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer</article-title>. <source>Clin Cancer Res</source> <volume>12</volume>: <fpage>3361</fpage>–<lpage>3367</lpage>.</citation>
</ref>
<ref id="bibr17-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cristofanilli</surname><given-names>M.</given-names></name>
<name><surname>Budd</surname><given-names>G.</given-names></name>
<name><surname>Ellis</surname><given-names>M.</given-names></name>
<name><surname>Stopeck</surname><given-names>A.</given-names></name>
<name><surname>Matera</surname><given-names>J.</given-names></name>
<name><surname>Miller</surname><given-names>M.</given-names></name>
<etal/>
</person-group>. (<year>2004</year>) <article-title>Circulating tumor cells, disease progression, and survival in metastatic breast cancer</article-title>. <source>N Engl J Med</source> <volume>351</volume>: <fpage>781</fpage>–<lpage>791</lpage>.</citation>
</ref>
<ref id="bibr18-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cristofanilli</surname><given-names>M.</given-names></name>
<name><surname>Hayes</surname><given-names>D.</given-names></name>
<name><surname>Budd</surname><given-names>G.</given-names></name>
<name><surname>Ellis</surname><given-names>M.</given-names></name>
<name><surname>Stopeck</surname><given-names>A.</given-names></name>
<name><surname>Reuben</surname><given-names>J.</given-names></name>
<etal/>
</person-group>. (<year>2005</year>) <article-title>Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer</article-title>. <source>J Clin Oncol</source> <volume>23</volume>: <fpage>1420</fpage>–<lpage>1430</lpage>.</citation>
</ref>
<ref id="bibr19-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Danila</surname><given-names>D.</given-names></name>
<name><surname>Heller</surname><given-names>G.</given-names></name>
<name><surname>Gignac</surname><given-names>G.</given-names></name>
<name><surname>Gonzalez-Espinoza</surname><given-names>R.</given-names></name>
<name><surname>Anand</surname><given-names>A.</given-names></name>
<name><surname>Tanaka</surname><given-names>E.</given-names></name>
<etal/>
</person-group>. (<year>2007</year>) <article-title>Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer</article-title>. <source>Clin Cancer Res</source> <volume>13</volume>: <fpage>7053</fpage>–<lpage>7058</lpage>.</citation>
</ref>
<ref id="bibr20-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dearnaley</surname><given-names>D.</given-names></name>
<name><surname>Mason</surname><given-names>M.</given-names></name>
<name><surname>Parmar</surname><given-names>M.</given-names></name>
<name><surname>Sanders</surname><given-names>K.</given-names></name>
<name><surname>Sydes</surname><given-names>M.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials</article-title>. <source>Lancet Oncol</source> <volume>10</volume>: <fpage>872</fpage>–<lpage>876</lpage>.</citation>
</ref>
<ref id="bibr21-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dearnaley</surname><given-names>D.</given-names></name>
<name><surname>Sydes</surname><given-names>M.</given-names></name>
<name><surname>Mason</surname><given-names>M.</given-names></name>
<name><surname>Stott</surname><given-names>M.</given-names></name>
<name><surname>Powell</surname><given-names>C.</given-names></name>
<name><surname>Robinson</surname><given-names>A.</given-names></name>
<etal/>
</person-group>. (<year>2003</year>) <article-title>A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial)</article-title>. <source>J Natl Cancer Inst</source> <volume>95</volume>: <fpage>1300</fpage>–<lpage>1311</lpage>.</citation>
</ref>
<ref id="bibr22-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dieli</surname><given-names>F.</given-names></name>
<name><surname>Vermijlen</surname><given-names>D.</given-names></name>
<name><surname>Fulfaro</surname><given-names>F.</given-names></name>
<name><surname>Caccamo</surname><given-names>N.</given-names></name>
<name><surname>Meraviglia</surname><given-names>S.</given-names></name>
<name><surname>Cicero</surname><given-names>G.</given-names></name>
<etal/>
</person-group>. (<year>2007</year>) <article-title>Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer</article-title>. <source>Cancer Res</source> <volume>67</volume>: <fpage>7450</fpage>–<lpage>7457</lpage>.</citation>
</ref>
<ref id="bibr23-1756287212453079">
<citation citation-type="confproc">
<person-group person-group-type="author">
<name><surname>Ebert</surname><given-names>R.</given-names></name>
<name><surname>Kaiser</surname><given-names>S.</given-names></name>
<name><surname>Meissner-Weigl</surname><given-names>J.</given-names></name>
<name><surname>Zeck</surname><given-names>S.</given-names></name>
<name><surname>Klein-Hitpass</surname><given-names>L.</given-names></name>
<name><surname>Rachner</surname><given-names>T.</given-names></name>
<etal/>
</person-group>. (<year>2011</year>) <article-title>Modulation of proliferation in MCF-7 cells by regulated expression of KLF2, KLF6 and Ki-67 after treatment with zoledronic acid</article-title>. <conf-name>Abstract presented at The European Multidisciplinary Cancer Congress</conf-name>, <conf-date>23–27 September 2011</conf-date>, <conf-loc>Stockholm, Sweden</conf-loc>. <comment>Abstract 5097</comment>.</citation>
</ref>
<ref id="bibr24-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ernst</surname><given-names>D.</given-names></name>
<name><surname>Tannock</surname><given-names>I.</given-names></name>
<name><surname>Winquist</surname><given-names>E.</given-names></name>
<name><surname>Venner</surname><given-names>P.</given-names></name>
<name><surname>Reyno</surname><given-names>L.</given-names></name>
<name><surname>Moore</surname><given-names>M.</given-names></name>
<etal/>
</person-group>. (<year>2003</year>) <article-title>Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain</article-title>. <source>J Clin Oncol</source> <volume>21</volume>: <fpage>3335</fpage>–<lpage>3342</lpage>.</citation>
</ref>
<ref id="bibr25-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fizazi</surname><given-names>K.</given-names></name>
<name><surname>Bosserman</surname><given-names>L.</given-names></name>
<name><surname>Gao</surname><given-names>G.</given-names></name>
<name><surname>Skacel</surname><given-names>T.</given-names></name>
<name><surname>Markus</surname><given-names>R.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial</article-title>. <source>J Urol</source> <volume>182</volume>: <fpage>509</fpage>–<lpage>515</lpage>; <comment>discussion follows</comment>.</citation>
</ref>
<ref id="bibr26-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fizazi</surname><given-names>K.</given-names></name>
<name><surname>Carducci</surname><given-names>M.</given-names></name>
<name><surname>Smith</surname><given-names>M.</given-names></name>
<name><surname>Damiao</surname><given-names>R.</given-names></name>
<name><surname>Brown</surname><given-names>J.</given-names></name>
<name><surname>Karsh</surname><given-names>L.</given-names></name>
<etal/>
</person-group>. (<year>2011</year>) <article-title>Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study</article-title>. <source>Lancet</source> <volume>377</volume>: <fpage>813</fpage>–<lpage>822</lpage>.</citation>
</ref>
<ref id="bibr27-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fizazi</surname><given-names>K.</given-names></name>
<name><surname>Lipton</surname><given-names>A.</given-names></name>
<name><surname>Mariette</surname><given-names>X.</given-names></name>
<name><surname>Body</surname><given-names>J.</given-names></name>
<name><surname>Rahim</surname><given-names>Y.</given-names></name>
<name><surname>Gralow</surname><given-names>J.</given-names></name>
<etal/>
</person-group>. (<year>2009</year>) <article-title>Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates</article-title>. <source>J Clin Oncol</source> <volume>27</volume>: <fpage>1564</fpage>–<lpage>1571</lpage>.</citation>
</ref>
<ref id="bibr28-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Garcia</surname><given-names>J.</given-names></name>
<name><surname>Rosenberg</surname><given-names>J.</given-names></name>
<name><surname>Weinberg</surname><given-names>V.</given-names></name>
<name><surname>Scott</surname><given-names>J.</given-names></name>
<name><surname>Frohlich</surname><given-names>M.</given-names></name>
<name><surname>Park</surname><given-names>J.</given-names></name>
<etal/>
</person-group>. (<year>2007</year>) <article-title>Evaluation and significance of circulating epithelial cells in patients with hormone-refractory prostate cancer</article-title>. <source>BJU Int</source> <volume>99</volume>: <fpage>519</fpage>–<lpage>524</lpage>.</citation>
</ref>
<ref id="bibr29-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gnant</surname><given-names>M.</given-names></name>
<name><surname>Mlineritsch</surname><given-names>B.</given-names></name>
<name><surname>Luschin-Ebengreuth</surname><given-names>G.</given-names></name>
<name><surname>Kainberger</surname><given-names>F.</given-names></name>
<name><surname>Kassmann</surname><given-names>H.</given-names></name>
<name><surname>Piswanger-Solkner</surname><given-names>J.</given-names></name>
<etal/>
</person-group>. (<year>2008</year>) <article-title>Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy</article-title>. <source>Lancet Oncol</source> <volume>9</volume>: <fpage>840</fpage>–<lpage>849</lpage>.</citation>
</ref>
<ref id="bibr30-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gnant</surname><given-names>M.</given-names></name>
<name><surname>Mlineritsch</surname><given-names>B.</given-names></name>
<name><surname>Stoeger</surname><given-names>H.</given-names></name>
<name><surname>Luschin-Ebengreuth</surname><given-names>G.</given-names></name>
<name><surname>Heck</surname><given-names>D.</given-names></name>
<name><surname>Menzel</surname><given-names>C.</given-names></name>
<etal/>
</person-group>. (<year>2011</year>) <article-title>Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial</article-title>. <source>Lancet Oncol</source> <volume>12</volume>: <fpage>631</fpage>–<lpage>641</lpage>.</citation>
</ref>
<ref id="bibr31-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Green</surname><given-names>J.</given-names></name>
<name><surname>Clezardin</surname><given-names>P.</given-names></name>
</person-group> (<year>2010</year>) <article-title>The molecular basis of bisphosphonate activity: a preclinical perspective</article-title>. <source>Semin Oncol</source> <volume>37</volume>(<supplement>Suppl. 1</supplement>): <fpage>S3</fpage>–<lpage>S11</lpage>.</citation>
</ref>
<ref id="bibr32-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hayes</surname><given-names>D.</given-names></name>
<name><surname>Cristofanilli</surname><given-names>M.</given-names></name>
<name><surname>Budd</surname><given-names>G.</given-names></name>
<name><surname>Ellis</surname><given-names>M.</given-names></name>
<name><surname>Stopeck</surname><given-names>A.</given-names></name>
<name><surname>Miller</surname><given-names>M.</given-names></name>
<etal/>
</person-group>. (<year>2006</year>) <article-title>Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival</article-title>. <source>Clin Cancer Res</source> <volume>12</volume>: <fpage>4218</fpage>–<lpage>4224</lpage>.</citation>
</ref>
<ref id="bibr33-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Henry</surname><given-names>D.</given-names></name>
<name><surname>Costa</surname><given-names>L.</given-names></name>
<name><surname>Goldwasser</surname><given-names>F.</given-names></name>
<name><surname>Hirsh</surname><given-names>V.</given-names></name>
<name><surname>Hungria</surname><given-names>V.</given-names></name>
<name><surname>Prausova</surname><given-names>J.</given-names></name>
<etal/>
</person-group>. (<year>2011</year>) <article-title>Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma</article-title>. <source>J Clin Oncol</source> <volume>29</volume>: <fpage>1125</fpage>–<lpage>1132</lpage>.</citation>
</ref>
<ref id="bibr34-1756287212453079">
<citation citation-type="confproc">
<person-group person-group-type="author">
<name><surname>Henry</surname><given-names>D.</given-names></name>
<name><surname>Von Moos</surname><given-names>R.</given-names></name>
<name><surname>Vadhan-Raj</surname><given-names>S.</given-names></name>
<name><surname>Hungria</surname><given-names>V.</given-names></name>
<name><surname>Spencer</surname><given-names>A.</given-names></name>
<name><surname>Hirsh</surname><given-names>V.</given-names></name>
<etal/>
</person-group>. (<year>2009</year>) <article-title>A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma</article-title>. <conf-name>Abstract presented at ECCO 15 and 34th ESMO Multidisciplinary Congress</conf-name>, <conf-date>20–24 September 2009</conf-date>, <conf-loc>Berlin, Germany</conf-loc>. <comment>Abstract LBA20</comment>.</citation>
</ref>
<ref id="bibr35-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Holen</surname><given-names>I.</given-names></name>
<name><surname>Croucher</surname><given-names>P.</given-names></name>
<name><surname>Hamdy</surname><given-names>F.</given-names></name>
<name><surname>Eaton</surname><given-names>C.</given-names></name>
</person-group> (<year>2002</year>) <article-title>Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells</article-title>. <source>Cancer Res</source> <volume>62</volume>: <fpage>1619</fpage>–<lpage>1623</lpage>.</citation>
</ref>
<ref id="bibr36-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Izumi</surname><given-names>K.</given-names></name>
<name><surname>Mizokami</surname><given-names>A.</given-names></name>
<name><surname>Itai</surname><given-names>S.</given-names></name>
<name><surname>Shima</surname><given-names>T.</given-names></name>
<name><surname>Shigehara</surname><given-names>K.</given-names></name>
<name><surname>Miwa</surname><given-names>S.</given-names></name>
<etal/>
</person-group>. (<year>2012</year>) <article-title>Increases in bone turnover marker levels at an early phase after starting zoledronic acid predicts skeletal-related events in patients with prostate cancer with bone metastasis</article-title>. <source>BJU Int</source> <volume>109</volume>: <fpage>394</fpage>–<lpage>400</lpage>.</citation>
</ref>
<ref id="bibr37-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Janni</surname><given-names>W.</given-names></name>
<name><surname>Vogl</surname><given-names>F.</given-names></name>
<name><surname>Wiedswang</surname><given-names>G.</given-names></name>
<name><surname>Synnestvedt</surname><given-names>M.</given-names></name>
<name><surname>Fehm</surname><given-names>T.</given-names></name>
<name><surname>Juckstock</surname><given-names>J.</given-names></name>
<etal/>
</person-group>. (<year>2011</year>) <article-title>Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse–a European pooled analysis</article-title>. <source>Clin Cancer Res</source> <volume>17</volume>: <fpage>2967</fpage>–<lpage>2976</lpage>.</citation>
</ref>
<ref id="bibr38-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kato</surname><given-names>Y.</given-names></name>
<name><surname>Tanaka</surname><given-names>Y.</given-names></name>
<name><surname>Miyagawa</surname><given-names>F.</given-names></name>
<name><surname>Yamashita</surname><given-names>S.</given-names></name>
<name><surname>Minato</surname><given-names>N.</given-names></name>
</person-group> (<year>2001</year>) <article-title>Targeting of tumor cells for human gammadelta T cells by nonpeptide antigens</article-title>. <source>J Immunol</source> <volume>167</volume>: <fpage>5092</fpage>–<lpage>5098</lpage>.</citation>
</ref>
<ref id="bibr39-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kawai</surname><given-names>T.</given-names></name>
<name><surname>Matsuyama</surname><given-names>T.</given-names></name>
<name><surname>Hosokawa</surname><given-names>Y.</given-names></name>
<name><surname>Makihira</surname><given-names>S.</given-names></name>
<name><surname>Seki</surname><given-names>M.</given-names></name>
<name><surname>Karimbux</surname><given-names>N.</given-names></name>
<etal/>
</person-group>. (<year>2006</year>) <article-title>B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease</article-title>. <source>Am J Pathol</source> <volume>169</volume>: <fpage>987</fpage>–<lpage>998</lpage>.</citation>
</ref>
<ref id="bibr40-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kijima</surname><given-names>T.</given-names></name>
<name><surname>Fujii</surname><given-names>Y.</given-names></name>
<name><surname>Suyama</surname><given-names>T.</given-names></name>
<name><surname>Okubo</surname><given-names>Y.</given-names></name>
<name><surname>Yamamoto</surname><given-names>S.</given-names></name>
<name><surname>Masuda</surname><given-names>H.</given-names></name>
<etal/>
</person-group>. (<year>2009</year>) <article-title>Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronate</article-title>. <source>BJU Int</source> <volume>103</volume>: <fpage>620</fpage>–<lpage>624</lpage>.</citation>
</ref>
<ref id="bibr41-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kijima</surname><given-names>T.</given-names></name>
<name><surname>Fujii</surname><given-names>Y.</given-names></name>
<name><surname>Suyama</surname><given-names>T.</given-names></name>
<name><surname>Okubo</surname><given-names>Y.</given-names></name>
<name><surname>Yonese</surname><given-names>J.</given-names></name>
<name><surname>Fukui</surname><given-names>I.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Lung and bone metastases from renal cell carcinoma responsive to bisphosphonates: a case report</article-title>. <source>Int J Urol</source> <volume>15</volume>: <fpage>546</fpage>–<lpage>547</lpage>.</citation>
</ref>
<ref id="bibr42-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kimmel</surname><given-names>D.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates</article-title>. <source>J Dent Res</source> <volume>86</volume>: <fpage>1022</fpage>–<lpage>1033</lpage>.</citation>
</ref>
<ref id="bibr43-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kimura</surname><given-names>S.</given-names></name>
<name><surname>Kuroda</surname><given-names>J.</given-names></name>
<name><surname>Segawa</surname><given-names>H.</given-names></name>
<name><surname>Sato</surname><given-names>K.</given-names></name>
<name><surname>Nogawa</surname><given-names>M.</given-names></name>
<name><surname>Yuasa</surname><given-names>T.</given-names></name>
<etal/>
</person-group>. (<year>2004</year>) <article-title>Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines</article-title>. <source>Int J Hematol</source> <volume>79</volume>: <fpage>37</fpage>–<lpage>43</lpage>.</citation>
</ref>
<ref id="bibr44-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kretzschmar</surname><given-names>A.</given-names></name>
<name><surname>Wiege</surname><given-names>T.</given-names></name>
<name><surname>Al-Batran</surname><given-names>S.</given-names></name>
<name><surname>Hinrichs</surname><given-names>H.</given-names></name>
<name><surname>Kindler</surname><given-names>M.</given-names></name>
<name><surname>Steck</surname><given-names>T.</given-names></name>
<etal/>
</person-group>. (<year>2007</year>) <article-title>Rapid and sustained influence of intravenous zoledronic acid on course of pain and analgesics consumption in patients with cancer with bone metastases: a multicenter open-label study over 1 year</article-title>. <source>Support Cancer Ther</source> <volume>4</volume>: <fpage>203</fpage>–<lpage>210</lpage>.</citation>
</ref>
<ref id="bibr45-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lipton</surname><given-names>A.</given-names></name>
<name><surname>Cook</surname><given-names>R.</given-names></name>
<name><surname>Saad</surname><given-names>F.</given-names></name>
<name><surname>Major</surname><given-names>P.</given-names></name>
<name><surname>Garnero</surname><given-names>P.</given-names></name>
<name><surname>Terpos</surname><given-names>E.</given-names></name>
<etal/>
</person-group>. (<year>2008</year>) <article-title>Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid</article-title>. <source>Cancer</source> <volume>113</volume>: <fpage>193</fpage>–<lpage>201</lpage>.</citation>
</ref>
<ref id="bibr46-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lipton</surname><given-names>A.</given-names></name>
<name><surname>Zheng</surname><given-names>M.</given-names></name>
<name><surname>Seaman</surname><given-names>J.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma</article-title>. <source>Cancer</source> <volume>98</volume>: <fpage>962</fpage>–<lpage>969</lpage>.</citation>
</ref>
<ref id="bibr47-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mariani</surname><given-names>S.</given-names></name>
<name><surname>Muraro</surname><given-names>M.</given-names></name>
<name><surname>Pantaleoni</surname><given-names>F.</given-names></name>
<name><surname>Fiore</surname><given-names>F.</given-names></name>
<name><surname>Nuschak</surname><given-names>B.</given-names></name>
<name><surname>Peola</surname><given-names>S.</given-names></name>
<etal/>
</person-group>. (<year>2005</year>) <article-title>Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma</article-title>. <source>Leukemia</source> <volume>19</volume>: <fpage>664</fpage>–<lpage>670</lpage>.</citation>
</ref>
<ref id="bibr48-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mason</surname><given-names>M.</given-names></name>
<name><surname>Sydes</surname><given-names>M.</given-names></name>
<name><surname>Glaholm</surname><given-names>J.</given-names></name>
<name><surname>Langley</surname><given-names>R.</given-names></name>
<name><surname>Huddart</surname><given-names>R.</given-names></name>
<name><surname>Sokal</surname><given-names>M.</given-names></name>
<etal/>
</person-group>. (<year>2007</year>) <article-title>Oral sodium clodronate for nonmetastatic prostate cancer–results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873)</article-title>. <source>J Natl Cancer Inst</source> <volume>99</volume>: <fpage>765</fpage>–<lpage>776</lpage>.</citation>
</ref>
<ref id="bibr49-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Matsumoto</surname><given-names>S.</given-names></name>
<name><surname>Kimura</surname><given-names>S.</given-names></name>
<name><surname>Segawa</surname><given-names>H.</given-names></name>
<name><surname>Kuroda</surname><given-names>J.</given-names></name>
<name><surname>Yuasa</surname><given-names>T.</given-names></name>
<name><surname>Sato</surname><given-names>K.</given-names></name>
<etal/>
</person-group>. (<year>2005</year>) <article-title>Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines</article-title>. <source>Lung Cancer</source> <volume>47</volume>: <fpage>31</fpage>–<lpage>39</lpage>.</citation>
</ref>
<ref id="bibr50-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Maxwell</surname><given-names>C.</given-names></name>
<name><surname>Swift</surname><given-names>R.</given-names></name>
<name><surname>Goode</surname><given-names>M.</given-names></name>
<name><surname>Doane</surname><given-names>L.</given-names></name>
<name><surname>Rogers</surname><given-names>M.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Advances in supportive care of patients with cancer and bone metastases: nursing implications of zoledronic acid</article-title>. <source>Clin J Oncol Nurs</source> <volume>7</volume>: <fpage>403</fpage>–<lpage>408</lpage>.</citation>
</ref>
<ref id="bibr51-1756287212453079">
<citation citation-type="confproc">
<person-group person-group-type="author">
<name><surname>Michaelson</surname><given-names>D.</given-names></name>
<name><surname>Kpamegan</surname><given-names>E.</given-names></name>
<name><surname>Perez</surname><given-names>J.</given-names></name>
<name><surname>Brown</surname><given-names>J.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Zoledronic acid (ZOL) reduces the incidence of skeletal-related events (SREs) and may improve survival in patients with bone metastases from renal cell carcinoma (RCC): a retrospective integrated analysis</article-title>. <conf-name>Abstract presented at 35th European Society for Medical Oncology Congress</conf-name>, <conf-date>8–12 October 2010</conf-date>, <conf-loc>Milan, Italy</conf-loc>. <comment>Abstract 917</comment>.</citation>
</ref>
<ref id="bibr52-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Miller</surname><given-names>P.</given-names></name>
<name><surname>Bolognese</surname><given-names>M.</given-names></name>
<name><surname>Lewiecki</surname><given-names>E.</given-names></name>
<name><surname>Mcclung</surname><given-names>M.</given-names></name>
<name><surname>Ding</surname><given-names>B.</given-names></name>
<name><surname>Austin</surname><given-names>M.</given-names></name>
<etal/>
</person-group>. (<year>2008</year>) <article-title>Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial</article-title>. <source>Bone</source> <volume>43</volume>: <fpage>222</fpage>–<lpage>229</lpage>.</citation>
</ref>
<ref id="bibr53-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mittan</surname><given-names>D.</given-names></name>
<name><surname>Lee</surname><given-names>S.</given-names></name>
<name><surname>Miller</surname><given-names>E.</given-names></name>
<name><surname>Perez</surname><given-names>R.</given-names></name>
<name><surname>Basler</surname><given-names>J.</given-names></name>
<name><surname>Bruder</surname><given-names>J.</given-names></name>
</person-group> (<year>2002</year>) <article-title>Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs</article-title>. <source>J Clin Endocrinol Metab</source> <volume>87</volume>: <fpage>3656</fpage>–<lpage>3661</lpage>.</citation>
</ref>
<ref id="bibr54-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Moreno</surname><given-names>J.</given-names></name>
<name><surname>Miller</surname><given-names>M.</given-names></name>
<name><surname>Gross</surname><given-names>S.</given-names></name>
<name><surname>Allard</surname><given-names>W.</given-names></name>
<name><surname>Gomella</surname><given-names>L.</given-names></name>
<name><surname>Terstappen</surname><given-names>L.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Circulating tumor cells predict survival in patients with metastatic prostate cancer</article-title>. <source>Urology</source> <volume>65</volume>: <fpage>713</fpage>–<lpage>718</lpage>.</citation>
</ref>
<ref id="bibr55-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Naoe</surname><given-names>M.</given-names></name>
<name><surname>Ogawa</surname><given-names>Y.</given-names></name>
<name><surname>Takeshita</surname><given-names>K.</given-names></name>
<name><surname>Morita</surname><given-names>J.</given-names></name>
<name><surname>Shichijo</surname><given-names>T.</given-names></name>
<name><surname>Fuji</surname><given-names>K.</given-names></name>
<etal/>
</person-group>. (<year>2010</year>) <article-title>Zoledronate stimulates gamma delta T cells in prostate cancer patients</article-title>. <source>Oncol Res</source> <volume>18</volume>: <fpage>493</fpage>–<lpage>501</lpage>.</citation>
</ref>
<ref id="bibr56-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Neville-Webbe</surname><given-names>H.</given-names></name>
<name><surname>Evans</surname><given-names>C.</given-names></name>
<name><surname>Coleman</surname><given-names>R.</given-names></name>
<name><surname>Holen</surname><given-names>I.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro</article-title>. <source>Tumour Biol</source> <volume>27</volume>: <fpage>92</fpage>–<lpage>103</lpage>.</citation>
</ref>
<ref id="bibr57-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Neville-Webbe</surname><given-names>H.</given-names></name>
<name><surname>Rostami-Hodjegan</surname><given-names>A.</given-names></name>
<name><surname>Evans</surname><given-names>C.</given-names></name>
<name><surname>Coleman</surname><given-names>R.</given-names></name>
<name><surname>Holen</surname><given-names>I.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells</article-title>. <source>Int J Cancer</source> <volume>113</volume>: <fpage>364</fpage>–<lpage>371</lpage>.</citation>
</ref>
<ref id="bibr58-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Noguchi</surname><given-names>M.</given-names></name>
<name><surname>Yahara</surname><given-names>J.</given-names></name>
<name><surname>Noda</surname><given-names>S.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer</article-title>. <source>Urology</source> <volume>61</volume>: <fpage>993</fpage>–<lpage>998</lpage>.</citation>
</ref>
<ref id="bibr59-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Oudard</surname><given-names>S.</given-names></name>
<name><surname>Smith</surname><given-names>M.</given-names></name>
<name><surname>Karsh</surname><given-names>L.</given-names></name>
<name><surname>Egerdie</surname><given-names>B.</given-names></name>
<name><surname>Van Veldhuizen</surname><given-names>P.</given-names></name>
<name><surname>Gómez-Veiga</surname><given-names>F.</given-names></name>
<etal/>
</person-group>. (<year>2011</year>) <article-title>Denosumab and bone metastasis-free survival in men with castrate-resistant prostate cancer - Subgroup analyses from an international, double-blind, randomized, phase 3 trial</article-title>. <source>Eur J Cancer</source> <volume>47</volume>: <fpage>S484</fpage>–<lpage>S485</lpage>.</citation>
</ref>
<ref id="bibr60-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pandha</surname><given-names>H.</given-names></name>
<name><surname>Birchall</surname><given-names>L.</given-names></name>
<name><surname>Meyer</surname><given-names>B.</given-names></name>
<name><surname>Wilson</surname><given-names>N.</given-names></name>
<name><surname>Relph</surname><given-names>K.</given-names></name>
<name><surname>Anderson</surname><given-names>C.</given-names></name>
<etal/>
</person-group>. (<year>2006</year>) <article-title>Antitumor effects of aminobisphosphonates on renal cell carcinoma cell lines</article-title>. <source>J Urol</source> <volume>176</volume>: <fpage>2255</fpage>–<lpage>2261</lpage>.</citation>
</ref>
<ref id="bibr61-1756287212453079">
<citation citation-type="confproc">
<person-group person-group-type="author">
<name><surname>Patrick</surname><given-names>D.</given-names></name>
<name><surname>Cleeland</surname><given-names>C.</given-names></name>
<name><surname>Fallowfield</surname><given-names>L.</given-names></name>
<name><surname>Smith</surname><given-names>M.</given-names></name>
<name><surname>Trachtenberg</surname><given-names>J.</given-names></name>
<name><surname>Chilingirov</surname><given-names>P.</given-names></name>
<etal/>
</person-group>. (<year>2011</year>) <article-title>Effects of denosumab and zoledronic acid on pain interference with daily functioning in patients with castrate-resistant prostate cancer</article-title>. <conf-name>Abstract presented at American Urology Association Meeting</conf-name>, <conf-date>14–19 May 2011</conf-date>, <conf-loc>Washington, DC, USA</conf-loc>. <comment>Abstract 711</comment>.</citation>
</ref>
<ref id="bibr62-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rosen</surname><given-names>L.</given-names></name>
<name><surname>Gordon</surname><given-names>D.</given-names></name>
<name><surname>Tchekmedyian</surname><given-names>N.</given-names></name>
<name><surname>Yanagihara</surname><given-names>R.</given-names></name>
<name><surname>Hirsh</surname><given-names>V.</given-names></name>
<name><surname>Krzakowski</surname><given-names>M.</given-names></name>
<etal/>
</person-group>. (<year>2004</year>) <article-title>Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial</article-title>. <source>Cancer</source> <volume>100</volume>: <fpage>2613</fpage>–<lpage>2621</lpage>.</citation>
</ref>
<ref id="bibr63-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Saad</surname><given-names>F.</given-names></name>
</person-group> (<year>2008</year>) <article-title>New research findings on zoledronic acid: survival, pain, and anti-tumour effects</article-title>. <source>Cancer Treat Rev</source> <volume>34</volume>: <fpage>183</fpage>–<lpage>192</lpage>.</citation>
</ref>
<ref id="bibr64-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Saad</surname><given-names>F.</given-names></name>
<name><surname>Clarke</surname><given-names>N.</given-names></name>
<name><surname>Colombel</surname><given-names>M.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Natural history and treatment of bone complications in prostate cancer</article-title>. <source>Eur Urol</source> <volume>49</volume>: <fpage>429</fpage>–<lpage>440</lpage>.</citation>
</ref>
<ref id="bibr65-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Saad</surname><given-names>F.</given-names></name>
<name><surname>Eastham</surname><given-names>J.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Zoledronic acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer</article-title>. <source>Urology</source> <volume>76</volume>: <fpage>1175</fpage>–<lpage>1181</lpage>.</citation>
</ref>
<ref id="bibr66-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Saad</surname><given-names>F.</given-names></name>
<name><surname>Gleason</surname><given-names>D.</given-names></name>
<name><surname>Murray</surname><given-names>R.</given-names></name>
<name><surname>Tchekmedyian</surname><given-names>S.</given-names></name>
<name><surname>Venner</surname><given-names>P.</given-names></name>
<name><surname>Lacombe</surname><given-names>L.</given-names></name>
<etal/>
</person-group>. (<year>2002</year>) <article-title>A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma</article-title>. <source>J Natl Cancer Inst</source> <volume>94</volume>: <fpage>1458</fpage>–<lpage>1468</lpage>.</citation>
</ref>
<ref id="bibr67-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Saad</surname><given-names>F.</given-names></name>
<name><surname>Gleason</surname><given-names>D.</given-names></name>
<name><surname>Murray</surname><given-names>R.</given-names></name>
<name><surname>Tchekmedyian</surname><given-names>S.</given-names></name>
<name><surname>Venner</surname><given-names>P.</given-names></name>
<name><surname>Lacombe</surname><given-names>L.</given-names></name>
<etal/>
</person-group>. (<year>2004</year>) <article-title>Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer</article-title>. <source>J Natl Cancer Inst</source> <volume>96</volume>: <fpage>879</fpage>–<lpage>882</lpage>.</citation>
</ref>
<ref id="bibr68-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Saad</surname><given-names>F.</given-names></name>
<name><surname>Lipton</surname><given-names>A.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers</article-title>. <source>BJU Int</source> <volume>96</volume>: <fpage>964</fpage>–<lpage>969</lpage>.</citation>
</ref>
<ref id="bibr69-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Saad</surname><given-names>F.</given-names></name>
<name><surname>Lipton</surname><given-names>A.</given-names></name>
<name><surname>Cook</surname><given-names>R.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Smith</surname><given-names>M.</given-names></name>
<name><surname>Coleman</surname><given-names>R.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Pathologic fractures correlate with reduced survival in patients with malignant bone disease</article-title>. <source>Cancer</source> <volume>110</volume>: <fpage>1860</fpage>–<lpage>1867</lpage>.</citation>
</ref>
<ref id="bibr70-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sato</surname><given-names>K.</given-names></name>
<name><surname>Yuasa</surname><given-names>T.</given-names></name>
<name><surname>Nogawa</surname><given-names>M.</given-names></name>
<name><surname>Kimura</surname><given-names>S.</given-names></name>
<name><surname>Segawa</surname><given-names>H.</given-names></name>
<name><surname>Yokota</surname><given-names>A.</given-names></name>
<etal/>
</person-group>. (<year>2006</year>) <article-title>A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo</article-title>. <source>Br J Cancer</source> <volume>95</volume>: <fpage>1354</fpage>–<lpage>1361</lpage>.</citation>
</ref>
<ref id="bibr71-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Scher</surname><given-names>H.</given-names></name>
<name><surname>Heller</surname><given-names>G.</given-names></name>
<name><surname>Molina</surname><given-names>A.</given-names></name>
<name><surname>Kheoh</surname><given-names>T.</given-names></name>
<name><surname>Attard</surname><given-names>G.</given-names></name>
<name><surname>Moreira</surname><given-names>J.</given-names></name>
<etal/>
</person-group>. (<year>2011</year>) <article-title>Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): planned final analysis (FA) of COU-AA-301, a randomized, double-blind, placebo-controlled, phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel</article-title>. <source>J Clin Oncol</source> <volume>29</volume>: <comment>Abstract LBA4517</comment>.</citation>
</ref>
<ref id="bibr72-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Serpa Neto</surname><given-names>A.</given-names></name>
<name><surname>Tobias-Machado</surname><given-names>M.</given-names></name>
<name><surname>Esteves</surname><given-names>M.</given-names></name>
<name><surname>Senra</surname><given-names>M.</given-names></name>
<name><surname>Wroclawski</surname><given-names>M.</given-names></name>
<name><surname>Fonseca</surname><given-names>F.</given-names></name>
<etal/>
</person-group>. (<year>2010</year>) <article-title>A systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma</article-title>. <source>BMC Urol</source> <volume>10</volume>: <fpage>9</fpage>.</citation>
</ref>
<ref id="bibr73-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Small</surname><given-names>E.</given-names></name>
<name><surname>Smith</surname><given-names>M.</given-names></name>
<name><surname>Seaman</surname><given-names>J.</given-names></name>
<name><surname>Petrone</surname><given-names>S.</given-names></name>
<name><surname>Kowalski</surname><given-names>M.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer</article-title>. <source>J Clin Oncol</source> <volume>21</volume>: <fpage>4277</fpage>–<lpage>4284</lpage>.</citation>
</ref>
<ref id="bibr74-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Smith</surname><given-names>M.</given-names></name>
<name><surname>Saad</surname><given-names>F.</given-names></name>
<name><surname>Coleman</surname><given-names>R.</given-names></name>
<name><surname>Shore</surname><given-names>N.</given-names></name>
<name><surname>Fizazi</surname><given-names>K.</given-names></name>
<name><surname>Tombal</surname><given-names>B.</given-names></name>
<etal/>
</person-group>. (<year>2012</year>) <article-title>Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial</article-title>. <source>Lancet</source> <volume>379</volume>: <fpage>39</fpage>–<lpage>46</lpage>.</citation>
</ref>
<ref id="bibr75-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Solomayer</surname><given-names>E-F.</given-names></name>
<name><surname>Gebauer</surname><given-names>G.</given-names></name>
<name><surname>Hirnle</surname><given-names>P.</given-names></name>
<name><surname>Janni</surname><given-names>W.</given-names></name>
<name><surname>Lück</surname><given-names>H-J.</given-names></name>
<name><surname>Becker</surname><given-names>S.</given-names></name>
<etal/>
</person-group>. (<year>2012</year>) <article-title>Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients</article-title>. <source>Ann Oncol</source> <month>Mar</month> <day>1</day>. <comment>Epub ahead of print</comment>.</citation>
</ref>
<ref id="bibr76-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tanvetyanon</surname><given-names>T.</given-names></name>
<name><surname>Stiff</surname><given-names>P.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Management of the adverse effects associated with intravenous bisphosphonates</article-title>. <source>Ann Oncol</source> <volume>17</volume>: <fpage>897</fpage>–<lpage>907</lpage>.</citation>
</ref>
<ref id="bibr77-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ullen</surname><given-names>A.</given-names></name>
<name><surname>Schwarz</surname><given-names>S.</given-names></name>
<name><surname>Lennartsson</surname><given-names>L.</given-names></name>
<name><surname>Kalkner</surname><given-names>K.</given-names></name>
<name><surname>Sandstrom</surname><given-names>P.</given-names></name>
<name><surname>Costa</surname><given-names>F.</given-names></name>
<etal/>
</person-group>. (<year>2009</year>) <article-title>Zoledronic acid induces caspase-dependent apoptosis in renal cancer cell lines</article-title>. <source>Scand J Urol Nephrol</source> <volume>43</volume>: <fpage>98</fpage>–<lpage>103</lpage>.</citation>
</ref>
<ref id="bibr78-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vogel</surname><given-names>C.</given-names></name>
<name><surname>Yanagihara</surname><given-names>R.</given-names></name>
<name><surname>Wood</surname><given-names>A.</given-names></name>
<name><surname>Schnell</surname><given-names>F.</given-names></name>
<name><surname>Henderson</surname><given-names>C.</given-names></name>
<name><surname>Kaplan</surname><given-names>B.</given-names></name>
<etal/>
</person-group>. (<year>2004</year>) <article-title>Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy</article-title>. <source>Oncologist</source> <volume>9</volume>: <fpage>687</fpage>–<lpage>695</lpage>.</citation>
</ref>
<ref id="bibr79-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wada</surname><given-names>T.</given-names></name>
<name><surname>Nakashima</surname><given-names>T.</given-names></name>
<name><surname>Hiroshi</surname><given-names>N.</given-names></name>
<name><surname>Penninger</surname><given-names>J.</given-names></name>
</person-group> (<year>2006</year>) <article-title>RANKL-RANK signaling in osteoclastogenesis and bone disease</article-title>. <source>Trends Mol Med</source> <volume>12</volume>: <fpage>17</fpage>–<lpage>25</lpage>.</citation>
</ref>
<ref id="bibr80-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wood</surname><given-names>J.</given-names></name>
<name><surname>Bonjean</surname><given-names>K.</given-names></name>
<name><surname>Ruetz</surname><given-names>S.</given-names></name>
<name><surname>Bellahcene</surname><given-names>A.</given-names></name>
<name><surname>Devy</surname><given-names>L.</given-names></name>
<name><surname>Foidart</surname><given-names>J.</given-names></name>
<etal/>
</person-group>. (<year>2002</year>) <article-title>Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid</article-title>. <source>J Pharmacol Exp Ther</source> <volume>302</volume>: <fpage>1055</fpage>–<lpage>1061</lpage>.</citation>
</ref>
<ref id="bibr81-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Woodward</surname><given-names>E.</given-names></name>
<name><surname>Jagdev</surname><given-names>S.</given-names></name>
<name><surname>Mcparland</surname><given-names>L.</given-names></name>
<name><surname>Clark</surname><given-names>K.</given-names></name>
<name><surname>Gregory</surname><given-names>W.</given-names></name>
<name><surname>Newsham</surname><given-names>A.</given-names></name>
<etal/>
</person-group>. (<year>2011</year>) <article-title>Skeletal complications and survival in renal cancer patients with bone metastases</article-title>. <source>Bone</source> <volume>48</volume>: <fpage>160</fpage>–<lpage>166</lpage>.</citation>
</ref>
<ref id="bibr82-1756287212453079">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Xgeva</surname><given-names>PI</given-names></name>
</person-group> (<year>2010</year>) <article-title>Xgeva (denosumab) prescribing information</article-title>. <publisher-loc>Thousand Oaks, CA</publisher-loc>: <publisher-name>Amgen Inc</publisher-name>.</citation>
</ref>
<ref id="bibr83-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yuasa</surname><given-names>T.</given-names></name>
<name><surname>Kimura</surname><given-names>S.</given-names></name>
<name><surname>Ashihara</surname><given-names>E.</given-names></name>
<name><surname>Habuchi</surname><given-names>T.</given-names></name>
<name><surname>Maekawa</surname><given-names>T.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Zoledronic acid – a multiplicity of anti-cancer action</article-title>. <source>Curr Med Chem</source> <volume>14</volume>: <fpage>2126</fpage>–<lpage>2135</lpage>.</citation>
</ref>
<ref id="bibr84-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zaghloul</surname><given-names>M.</given-names></name>
<name><surname>Boutrus</surname><given-names>R.</given-names></name>
<name><surname>El-Hossieny</surname><given-names>H.</given-names></name>
<name><surname>Kader</surname><given-names>Y.</given-names></name>
<name><surname>El-Attar</surname><given-names>I.</given-names></name>
<name><surname>Nazmy</surname><given-names>M.</given-names></name>
</person-group> (<year>2010</year>) <article-title>A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer</article-title>. <source>Int J Clin Oncol</source> <volume>15</volume>: <fpage>382</fpage>–<lpage>389</lpage>.</citation>
</ref>
<ref id="bibr85-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zekri</surname><given-names>J.</given-names></name>
<name><surname>Ahmed</surname><given-names>N.</given-names></name>
<name><surname>Coleman</surname><given-names>R.</given-names></name>
<name><surname>Hancock</surname><given-names>B.</given-names></name>
</person-group> (<year>2001</year>) <article-title>The skeletal metastatic complications of renal cell carcinoma</article-title>. <source>Int J Oncol</source> <volume>19</volume>: <fpage>379</fpage>–<lpage>382</lpage>.</citation>
</ref>
<ref id="bibr86-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Dai</surname><given-names>J.</given-names></name>
<name><surname>Qi</surname><given-names>Y.</given-names></name>
<name><surname>Lin</surname><given-names>D.</given-names></name>
<name><surname>Smith</surname><given-names>P.</given-names></name>
<name><surname>Strayhorn</surname><given-names>C.</given-names></name>
<etal/>
</person-group>. (<year>2001</year>) <article-title>Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone</article-title>. <source>J Clin Invest</source> <volume>107</volume>: <fpage>1235</fpage>–<lpage>1244</lpage>.</citation>
</ref>
<ref id="bibr87-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Dai</surname><given-names>J.</given-names></name>
<name><surname>Yao</surname><given-names>Z.</given-names></name>
<name><surname>Lu</surname><given-names>Y.</given-names></name>
<name><surname>Dougall</surname><given-names>W.</given-names></name>
<name><surname>Keller</surname><given-names>E.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone</article-title>. <source>Cancer Res</source> <volume>63</volume>: <fpage>7883</fpage>–<lpage>7890</lpage>.</citation>
</ref>
<ref id="bibr88-1756287212453079">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Zometa</surname><given-names>PI</given-names></name>
</person-group> (<year>2011</year>) <article-title>Zometa (zoledronic acid) prescribing information</article-title>. <publisher-loc>East Hanover, NJ</publisher-loc>: <publisher-name>Novartis Pharmaceuticals Corporation</publisher-name>.</citation>
</ref>
<ref id="bibr89-1756287212453079">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zwolak</surname><given-names>P.</given-names></name>
<name><surname>Manivel</surname><given-names>J.</given-names></name>
<name><surname>Jasinski</surname><given-names>P.</given-names></name>
<name><surname>Kirstein</surname><given-names>M.</given-names></name>
<name><surname>Dudek</surname><given-names>A.</given-names></name>
<name><surname>Fisher</surname><given-names>J.</given-names></name>
<etal/>
</person-group>. (<year>2010</year>) <article-title>Cytotoxic effect of zoledronic acid-loaded bone cement on giant cell tumor, multiple myeloma, and renal cell carcinoma cell lines</article-title>. <source>J Bone Joint Surg Am</source> <volume>92</volume>: <fpage>162</fpage>–<lpage>168</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>